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Actin remodelling is essential to many dynamic cellular processes such 
as morphogenesis, motility, differentiation and endocytosis. These changes are 
controlled by Rho GTPases that cycle between the active GTP- and inactive 
GDP-bound forms, which in turn are tightly regulated by guanine nucleotide 
exchange factors (GEFs), GTPase activating protein (GAPs) and the guanine 
nucleotide dissociation inhibitor (GDIs). Deleted in Liver Cancer-1 (DLC1), is 
a bona fide tumor suppressor GTPase activating protein (GAP) acting 
preferentially on Rho. It is a multi-domain protein, consisting of N-terminal 
SAM domain, C-terminal START domain and the catalytic RhoGAP domain. 
This allows for its interaction with diverse cellular proteins, including FAK, 
Tensins and Talin, all of which are focal adhesion-associated proteins, as well 
as other scaffolding, regulatory proteins such as 14-3-3, EF1A1, and 
S100A10. As such, the tumor suppressive function of DLC1 can be mediated 
in a GAP-dependent or GAP-independent manner. Interestingly, DLC1 also 
contains a serine-rich region which is a phosphorylation hot-spot and is 
thought to be modified downstream of several potential kinases such as Akt, 
RSK and PKC/PKD. Despite all these, the nature of DLC1s activation and 
inactivation remains largely unknown. Here we elucidate a novel pathway 
involving the concerted action of Ras/Mek/Erk pathway, Focal adhesion 
kinase (FAK) and Protein phosphatase-2A (PP2A) to activate DLC1s GAP 
function. EGF stimulation not only leads to the phosphorylation of DLC1 but 
also that of FAK to inactivate it, thus allowing PP2A-mediated 
dephosphorylation at a secondary site on DLC1. This signalling cascade 
directly affects DLC1s effect on cell spreading and migration, which can be 
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1   Introduction 
 
Cell migration in all multicellular organisms, is a process that is 
essential starting from development and playing a role in later stages during 
processes such as immune surveillance and wound healing. Migration is 
controlled by extracellular cues which direct the movement of the cell. These 
cues control the process by eliciting a multitude of cellular changes such as 
actin cytoskeletal reorganization, gene transcription and vesicular transport 
[Raftopoulou and Hall, 2004]. Not only is cell migration important in 
physiological processes, it also plays a role in cancer progression. The 
migratory process is similar in both physiological conditions and cancer. What 
is different is that in cancer cells the signals activating migration are dominant 
over the ones controlling its inhibition and it is this imbalance that allow the 
tumor cells to metastasize [Friedl and Wolf, 2003].  
Many signalling pathways are involved in cell migration and small 
GTPases are one of the key molecules. These molecules are under tight spatio-
temporal regulation [Pertz, 2010]. Upon dysregulation, they increase the 
migratory behaviour of the cells and are also seen to be up-regulated in 
Epithelial-Mesenchymal Transition (EMT) which is a necessary step for a 
tumor cell to become invasive [Friedl and Wolf, 2003; Yamaguchi et al., 
2005]. In the coming sections we will discuss a sub-family of small GTPases, 
namely, RhoGTPases their regulation and role in cancer as well as a tumor 
suppressor which has been identified as a regulator of RhoGTPases. 
1.1 Ras Superfamily: 
 
The Ras superfamily of proteins is a group of small guanosine 
triphosphatases (GTPases). These proteins are similar in their functions and 
biochemistry to the heteromeric G proteins α subunit but they function as 
monomeric G proteins [Wennerberg et al., 2005]. This superfamily comprises 
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of about 150 members in the humans and has orthologues in Drosophila, C. 
elegans, S. cerevisiae, S. pombe, Dictyostelium and plants, all of which are 
evolutionarily conserved [Colicelli, 2004]. The Ras, identified as an 
oncoprotein in Rat sarcoma, is the founding member of the family that is 
divided into five subfamilies based on their sequence, structural and functional 
similarities, namely: Ras, Rho (Ras homology), Ran (Ras-like nuclear 
proteins), Arf (ADP-ribosylation factor) and Rab (Ras-like proteins in the 
brain) (Fig 1.1).  
 
 
Figure 1.1: Ras superfamily of proteins [Takai et al., 2001] 
 
This group of proteins act as binary molecular switches and based on 
the structural differences and post-translational modifications, these proteins 
localize to different sub-cellular compartments, where they exert their 
functions to regulate a multitude of cellular processes, such as proliferation 
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and cell survival in the case of Ras, actin-cytoskeleton remodelling by Rho, 
intracellular vesicular transport and protein trafficking by the Rab and Arf 
subfamily, nucleocytoplasmic transport RanGTPases and mitochondrial 
integrity in the case of Miro.  
Ras superfamily GTPases, as molecular switches, alternate between 
GDP-bound and GTP-bound states. The G domain of the superfamily is about 
20 kDa and is not only conserved amongst the Ras superfamily but also in Gα 
and other GTPases. At the N-terminus they have a set of G box with 
GTP/GDP-binding motifs: G1 (GXXXXGKS/T), G2 (T), G3 (DXXGQ/H/T), 
G4 (T/NKXD) and G5 (C/SAK/L/T).  
 
1.2 Rho-GTPase family 
 
Rho was initially discovered as a Ras-related protein in 1985 in 
Aplysia [Hall, 2012] and to date about 20 human proteins have identified in 
this family, with Rho, Rac and Cdc42 being the best characterized 
[Wennerberg et al., 2005]. The Rho subfamily itself can be further divided 
into 5 groups: Rho-like, Rac-like, Cdc42-like, Rnd, and RhoBTB [Burridge 
and Wennerberg, 2004]. To this classification a 6
th
 group, known as Miro can 
be added, which is an atypical GTPase [Wennerberg and Der, 2004]. Figure 






Figure 1.2: Rho subfamily of proteins [Grise et al., 2009]. 
 
1.2.1 RhoGTPases: Binary molecular switches 
  
 The RhoGTPases like most of the members of the Ras superfamily 
function as binary molecular switches cycling between the active GTP-bound 
form and the inactive GDP bound form [Vetter and Wittinghofer, 2001]. 
Compared to the other members of the Ras superfamily, the RhoGTPases have 
an insertion of 13 amino acid motif into its G-domain [Wennerberg and Der, 
2004]. This G-domain forms a conserved α/β structure, folding into a shallow 
pocket at the surface to accommodate the guanine nucleotide [Scheffzek and 
Ahmadian, 2005]. For mediating the binding with the guanine nucleotides, the 
G-domain contains two switch regions (Switch I and Switch II) and a 
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phosphate binding loop or the P-loop, which allow for interactions with the γ-
phosphates of the guanosine nucleotides [Vetter and Wittinghofer, 2001]. 
 In the “ON” state, GDP gets exchanged for GTP [Vetter and 
Wittinghofer, 2001] which results in a conformational change in the G-domain 
as both the Switch I and II regions directly make contact with the γ-phosphate, 
which presents a binding surface that allows for recognition and binding of the 
downstream effectors, leading to their activation. Whereas in the “OFF” state, 
there is an irreversible hydrolysis of GTP to GDP, leading to the release of the 
γ-phosphate. This leads to a conformational change, releasing the effector 
proteins which now have reduced affinity for this state [Scheffzek and 
Ahmadian, 2005; Vetter and Wittinghofer, 2001]. The hydrolysis to bring 
about inactivation of RhoGTPases is mediated by the intrinsic, albeit slow, 
GTPase activity of the G-domain. The exchange of the GDP for GTP starts off 
the next cycle, allowing for a control of the downstream signalling.  
Since the RhoGTPases regulate various important cellular processes, 
there has to be a tight and efficient control of their switching between the two 
states. For this regulation, there are three classes of molecules, namely:  GEFs 
(guanine nucleotide exchange factors), GAPs (GTPase-activating proteins) 
and GDIs (guanine nucleotide dissociation inhibitors). Figure 1.3 summarizes 
the RhoGTPase cycle. 
 
1.2.2 RhoGTPases: Regulators 
 
To ensure signalling specificity and timely turning ON and OFF of 
RhoGTPase cycle, not only do RhoGTPases themselves get modified but there 
are other regulators of RhoGTPases as mentioned earlier. There are 82 GEFs, 
67 GAPs and 3 GDIs which control the RhoGTPases [Lahoz and Hall, 2008]. 
Each RhoGTPase can be regulated by multiple GAPs and GEFs, while GAPs 
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and GEFs are very specific in their function [Wennerberg et al., 2005].  GDI 




Figure 1.3:  RhoGTPase as a binary switch and its regulators [Fukata and 
Kaibuchi, 2001]. 
 
conditions. In the event of a stimulus, GDIs release the RhoGTPases, leading 
to interaction with GEFs which catalyse the activation by allowing for 
exchange of GDP for GTP. To enhance the intrinsic GTPase function and 
attenuate the signal, GAPs get recruited to the RhoGTPase. This GDP-bound 
RhoGTPase now binds the GDI again and remains in the cytosol until the next 







1.2.2.1 Rho GDI 
 
There are three GDIs expressed in humans namely, RhoGDI-1, -2 and 
-3. While RhoGDI-1 is ubiquitous in its expression pattern, RhoGDI-2 is 
hematopoietic-specific and RhoGDI-3 are found to be expressed only in the 
testis, lung and brain [DerMardirossian and Bokoch, 2005].  The switch region 
of RhoGTPase get prenylated, leading to its binding with GDI, which leads to 
the sequestration of RhoGTPase in the cytosol by preventing the C-terminal 
lipid modifications needed for its translocation to the plasma membrane 
[Seabra and Wasmeier, 2004]. GDIs carry out their inhibition of RhoGTPase 
function in three main ways. First of all, they prevent the dissociation of GDP 
from RhoGTPases by inhibiting the activation by GEFs. Next, they interact 
with the GTP-bound form, preventing the action of the internal as well as GAP 
mediated hydrolysis, interrupting the active binding with the downstream 
effectors. Finally, they modulate the RhoGTPase translocation from the 
cytosol to their site of action [DerMardirossian and Bokoch, 2005]. 
GTPases, to a large extent, exist in their inactive form as suggested by 
the existence of comparable amount of GDIs in relation to the RhoGTPase 
concentration in the cells. Hence, GDI are a key regulation component of the 
GTPase functions [Michaelson et al., 2001]. 
 
1.2.2.2 Rho GEFs  
 
GTP hydrolysis to GDP is an irreversible step. For the next round of 
activation, GDP has to be dissociated from the RhoGTPase before it can be 
loaded with GTP, making this the rate limiting step in the RhoGTPase cycle 
[Erickson and Cerione, 2004]. GEFs catalyse this step, allowing the timely 
activation of the RhoGTPases. In humans, there are 85 GEFs present. These 
are activated downstream of growth factor receptor stimulation.  They are 
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usually found as a part of signalling complexes brought together by 
scaffolding proteins, allowing for specificity [Bos et al., 2007]. The affinity of 
RhoGTPase is the same for GTP and GDP and GEF does not work by 
favouring the binding of either over the other. Instead, GEFs function by 
modifying the nucleotide binding site that consists of the two switch regions 
and the P-loop, weakening the affinity of that site to bind nucleotide. This 
exchange is also mediated by the fact that the affinity of the binary complex 
(GTPase for either the nucleotide or the GEF) is much higher than the affinity 
of the ternary complex (GEF for a nucleotide-bound G protein or nucleotide 
for a GEF-bound G protein). Hence, the nucleotide gets displaced upon GEF 
binding to the GTPase and the replacing nucleotide displaces the GEF from it. 
Since, GEF does not favour the binding of either GDP or GTP, the GTP 
loading on the GTPase is determined by the fact that there is ten times higher 
concentration of GTP in the cell [Bos et al., 2007; Vetter and Wittinghofer, 
2001].   
GEFs are also in turn controlled by regulatory mechanisms which 
control their translocation to site of GTPase regulation, removal of the auto-
inhibition and bring about changes in their catalytic domain. Factors that 
usually control this are: post-translational modifications, interaction with 
second messengers, other proteins as well as lipids [Bos et al., 2007]. GEFs 
have been identified as oncogenes, not surprisingly, as they up-regulate 
RhoGTPases which have a role to play in cancer [Hall, 2005].   
 
1.2.2.3 Rho GAPs 
 
Since the intrinsic GTPase of the G protein is extremely slow to be 
able to catalyse the hydrolysis of GTP to GDP by itself, it requires RhoGAP as 
a catalyst. The GAPs mainly function by stabilizing the intrinsic, highly 
mobile, catalytic domain of the GTPases as well as inserting a catalytic 
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residue in trans. GAP mediated hydrolysis is composed of various steps, 
which involves orienting the water molecule for a nucleophilic attack [Vetter 
and Wittinghofer, 2001], obstructing the water from entering the active site as 
well as stabilizing the transition state [Bos et al., 2007]. GAPs contain a 
conserved arginine residue, known as the arginine finger, that causes the 
neutralization of the negative charge on the γ-phosphate, which stabilizes the 
transition state [Rittinger et al., 1997]. Mutating the arginine residue renders 
the GAP inactive, demonstrating the importance of the residue to GAP 
function. Also, the stabilizing of the glutamine 61 residue by the GAPs, allows 
for the optimal positioning for the attack by the water molecule [Scheffzek and 
Ahmadian, 2005]. Also, this restricts the movement of the water molecule 
lowering the energy barrier for hydrolysis of GTP [Nassar et al., 1998].   
 GAPs are regulated by mechanisms similar to that of GEFs via binding 
of secondary messengers, other proteins and lipids and post-translational 
modifications [Bos et al., 2007]. GAPs act as tumor suppressor since they 
function to inhibit RhoGTPase mediated cellular processes. They are seen to 
be more frequently mutated in cancers as compared to the GEFs.  
.  
1.2.3 Rho GTPases: Downstream effectors 
 
Conformational change brought about by the activation of 
RhoGTPases, leads to binding of the downstream effector targets, which in 
turn get activated to bring about cellular changes. Of the 23 Rho family 
proteins known, the best studied ones are Rho, Rac and Cdc42. There are over 
50 effectors that have been identified for them, including serine/threonine 
kinases, tyrosine kinases, lipid kinases, lipases, oxidases and scaffold proteins 
[Jaffe and Hall, 2005]. The most common mechanism of activation by 
RhoGTPases is by disrupting the intramolecular autoinhibitory interactions in 
the effector proteins. Also, it is seen that quite a few of the effector proteins of 
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RhoGTPases contain a coiled-coil region which allows for oligomerization 
[Bishop and Hall, 2000].  
The main target proteins for Rho are serine/threonine kinases like 
ROCK (Rho Kinase) and scaffold proteins (Dia). Through their coiled-coil 
regions, these effectors recognize and bind active Rho [Bishop and Hall, 
2000]. Rho-mediated downstream functions mainly include actin cytoskeletal 
reorganization. The Ser/Thr kinases, ROCK1 and ROCK2, are both 
ubiquitously expressed, and have 64% identity with their kinase domains 
having the maximum similarity. ROCK promotes Rho-mediated increase in 
cellular contractility by cross-linking actin and myosin. Effect of ROCK on 
the actin and myosin leads to changes in cell motility, adhesion, smooth 
muscle contraction, neurite retraction, and phagocytosis [Riento and Ridley, 
2003]. mDia is a formin molecule that promotes the actin nucleation and 
polymerization to form elongated actin filaments [Narumiya et al., 2009]. The 
coordination between ROCK and mDia leads to actin reorganization 
downstream of Rho [Watanabe et al., 1999].   
Rac and Cdc42 on the other hand seem to have common effectors. This 
can be attributed to about 70% sequence identity amongst them. The 
downstream effectors of the these two have a common motif known as CRIB 
(Cdc42/Rac-interactive binding) motif [Hakoshima et al., 2003]. This motif 
was initially identified in p21-activated protein kinase 1 (PAK1) which 
belongs to the PAK family and regulate cell motility, cell survival and cell 
cycle progression [Bishop and Hall, 2000; Bokoch, 2003]. Crystal structures 
of activated Cdc42-associated kinase (ACK), Wiskott-Aldrich syndrome 
protein (WASP) and partition-defective protein (Par6) and PAK1 have shown 
that the CRIB motif is important for interaction with the RhoGTPases and it 
forms an intermolecular β-sheet with Rac and Cdc42 [Hakoshima et al., 2003]. 
WAVE2 belongs to the Wiskott–Aldrich syndrome protein (WASP) family, 
which consists of the WASP subfamily and the WAVE subfamily (WASP 
family verprolin-homologous protein). These are scaffold proteins which 
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directly bind to and activate the Arp2/3 complex, leading to actin 
polymerization and filopodia formation [Takenawa and Suetsugu, 2007].  
1.2.4 RhoGTPases: Cellular functions  
 
The RhoGTPases induce, in response to external stimuli, a cascade of 
synchronized changes in the actin cytoskeleton and the transcription to bring 
about various changes at the physiological level. These changes include 
morphogenesis, chemotaxis, vesicle transport, cell polarity, axonal guidance, 
and cell cycle progression and upon dysregulation are seen to play a role in 
oncogenesis.  
 
1.2.4.1 Cell cycle regulation 
 
In the cell cycle, the G1-S phase progression, mitosis and cytokinesis 
are all in some way or the other controlled by RhoGTPase activity. G1-S 
progression depends on the regulation of cyclin and Cdk inhibitors. Cyclin 
concentrations are affected by maintaining the levels of ERK and by 
extracellular matrix proteins. Rho proteins act at this level to regulate this 
phase. The RhoGTPases also trigger the transcription of cyclin D and activate 
the Serum Response Factor (SRF).  They are important for serum-induced G1 
progression as well as Ras-induced cell transformation [Hall, 1998; Jaffe and 







Mitosis and cytokinesis regulation is affected by the ability 
of RhoGTPases to act on the cytoskeletal components [Jaffe and Hall, 2005]. 
Rho and Cdc42 also play a role in the formation of the actomyosin contractile 




1.2.4.2 Cytoskeletal dynamics and cell movement 
The activity of RhoGTPases on the actin cytoskeleton is conserved in 
all eukaryotes. Involvement of RhoGTPases in cytoskeletal dynamics was first 
seen when Rho and Rac, in response to stimulus regulated the actin assembly 
and organization. In response to lysophosphatidic acid (LPA) or integrin 
engagement, Rho leads to the formation of stress fibers and focal adhesions. 
Rac on the other hand, in response to platelet-derived growth factor (PDGF) or 
insulin, forms lamellipodia and membrane ruffles by the virtue of promoting 
assembly of the peripheral actin network, while response from Cdc42 was 
elicited upon stimulation by bradykinin and interleukin 1 (IL-1), leading to the 
formation of filopodia, by actin bundling at the cell periphery. Rho brings 
about changes in the actin cytoskeleton through its interaction with ROCK and 
mDia. ROCK in turn phosphorylates myosin light chain phosphatase (MLCP) 
to inactivate it and hence ensuring phosphorylation of myosin by myosin light 
chain kinase (MLCK). This leads to actin-myosin cross-linking, triggering cell 
contraction. Rac and Cdc42 exert their influence by activating Arp2/3 through 
their interactions with WAVE and WASP respectively, which leads to the 
elongation of the peripheral F-actin generating a meshwork [Hall, 2012; 
Nobes and Hall, 1995; Ridley and Hall, 1992].  
The dynamic rearrangement of the cytoskeleton drives cell migration. 
The coordinated effect of all three Rho GTPases is required to bring about the 
changes at the front and the rear end of the cell for a directed cell movement. 
Cdc42 determines the polarity of the cells by sensing the extracellular cues, 
and the direction of the cell movement. It also determines the regions of Rac 
accumulation. At the leading edge, Rac, by forming the membrane protrusions 
drives the forward movement of the cell. Rho, at the rear of the cell induces 
stress fibre formation causing cell body contraction, which also allows the cell 
to move forward. Apart from these changes, both the cell-cell adhesion as well 
as cell-matrix adhesions determine cell migration and are also regulated by the 
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RhoGTPases [Fukata et al., 1999]. In cell-matrix adhesions, Rho is required 
for the assembly of integrin-based focal complexes. Rho GTPases also 
regulate the formation and maintenance of specialised cadherin-based 
junctional adhesion complexes known as the tight junctions and adherens 
junctions. Formation of cell-matrix adhesions allows the progression of cell 
migration, whereas the cell-cell junctions inhibit the cell migration. Apart 
from controlling the actin dynamics, Rho GTPases also influence microtubule 
dynamics by regulating the microtubule plus end-binding proteins [Hall, 2012; 
Jaffe and Hall, 2005; Malliri and Collard, 2003]. 
 
1.2.5 Rho GTPases: Cancer 
 
RhoGTPases are involved in various stages of tumorigenesis. It has 
been shown that Rho proteins not only regulate the cytoskeletal reorganization 
and hence cell morphology, but also have potent effect on cell proliferation, 
gene expression and apoptosis. These effects are generally mediated by over-
expression of the proteins and in some cases point mutations and alternatively 
spliced form [Fritz et al., 2002].  This can lead to aberrant RhoGTPase 
signalling. Also, activated Rho mutants can independently transform cells 
albeit to a lesser degree as compared to the Ras mutants. They also co-operate 
with Raf for this purpose. The deregulation of RhoGTPases has been shown to 
correlate with poor cancer prognosis.  As RhoGTPases are important 
regulators of cell migration, their deregulation will lead to metastasis in tumor 
cells. This also leads to loss of polarity in migrating cells and they are 
probably one of the factors involved in EMT.  RhoGTPase dysregulation can 
also lead to breakdown of the cell cycle as they control CDKs which in turn 
control the cell cycle. Cancer cells do not have apoptotic properties and there 
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is evidence of Rho-proteins being involved in anti-apoptotic pathways.  [Sahai 
and Marshall, 2002]. 
 
1.2.6 Rho GAP-containing proteins are critical regulators of diverse 
cellular activities  
 
 The RhoGAP family of proteins is defined by the presence of a GAP 
domain with activity towards RhoGTPases. It consists of 150 amino acids and 
shares 20% sequence identity with other GAP domains in the family. There 
are about 70 RhoGAPs that have been identified in the humans, compared to 
only 20 RhoGTPases. The high number of RhoGAPs suggests that each GAP 
has a very specific function and is under a very tight spatial and temporal 
regulation. This domain consists of nine alpha helices as well as the highly 
conserved “Arginine finger” that is the key to its GAP function [Moon and 
Zheng, 2003]. 
 Apart from the GAP domain, RhoGAP proteins contain various other 
domains that help in determining their subcellular location and interacting 
partners. Some of the well-characterized domains are Src Homology 2 and 3 
(SH2 and 3) domains that allow for protein-protein interactions, pleckstrin 
homology (PH) and bin-amphiphysin-rvs (BAR) domains which are lipid 
interaction domains and allow GAPs to be targeted to the membranes. These 
domains also serve as scaffolds for protein complex formation [Bos et al., 
2007]. RhoGAPs also contain other catalytic domains which make them points 
of convergence or divergence in the RhoGTPase cycle. For example, they may 
contain a GEF domain, which allows for simultaneous regulation of different 
Rho family members [Chuang et al., 1995]. Some GAP domain-containing 
proteins have no known RhoGAP function, in which case they might just 
simply serve as a RhoGTPase binding domain like in the case of p85 [Zheng 
et al., 1994].   
16 
 
1.2.6.1 Mechanisms of Rho GAP regulation  
 
Because the RhoGAPs outnumber their downstream effectors, they are 
under a strict regulation, both spatially and temporally to ensure that the 
RhoGTPases are not perpetually in an inactive state.  Phosphorylation, 
protein-protein interaction, phospholipid binding and proteolytic degradation 
are the main events that regulate RhoGAP function.  
 
Protein-protein interaction:  The RhoGAPs have various protein 
interaction domains, which regulate their GAP function by either activating 
them or inactivating them. Examples of the interaction inactivating GAP 
activity are the binding of intersectin, a scaffold protein, to CdGAP and 
TCGAP with Fyn Kinase (Moon and Zheng, 2003; Jenna et al., 2002). On the 
other hand, interaction of RA-RhoGAP with Rap1 activates the GAP function 
by removing the auto-inhibition (Yamada et al 2005). The protein interaction 
can also be for the purpose of targeting the GAP to a particular subcellular 
location without affecting the GAP function as is the case with p120RasGAP 
and p190RhoGAP (Bradley et al., 2006). Interaction of the Ras/Rap1-
associating (RA) domain in RA-RhoGAP with Rap1 was also found to release 
the Rho GAP from auto-inhibition, thereby inducing GAP activity (Yamada et 
al., 2005).  
 
Phospholipid-binding: The association of Rho GAPs with 
phospholipids usually leads to the translocation of the RhoGAP to the plasma 
membrane, bringing it in contact with the RhoGTPase it exerts its function on 
like in the case of phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) interaction 
with ARAP3 RhoGAP (Krugmann et al., 2004). Also, as phospholipids are 
associated with growth factor signalling, binding of RhoGAPs to them could 




Phosphorylation: Phosphorylation is a common regulatory event seen 
in proteins and RhoGAPs are no exception. In p190RhoGAP, phosphorylation 
by insulin growth factor receptors led to its localization from the cytosol to the 
plasma membrane (Sordella et al., 2003). Whereas in MgcRacGAP, a 
Rac1/Cdc42 GAP, serine phosphorylation changes its effector specificity to 
RhoA (Lee et al., 2004). Deleted in Liver Cancer1 (DLC1), a GAP for RhoA, 
gets inactivated upon phosphorylation by Akt [Ko et al., 2010b].  
 
Proteolytic degradation: Rho GAPs can be regulated temporally 
through proteolytic degradation which controls its turnover rate. Levels of 
p190RhoGAP determine the cytokinesis completion. These levels are in turn 
determined by ubiquitin-mediated degradation of the RhoGAP (Su et al., 
2003). Another RhoGAP, DLC1 was seen to be susceptible to degradation by 
the 26S proteasome [Luo et al., 2011]. DLC1 is the protein of interest in our 
study and will be discussed in detail in the following sections. 
 
1.2.6.2 RhoGAPs: Effects on cellular processes 
 
With RhoGTPases regulating cell processes such as trafficking, 
endocytosis, cell growth and differentiation and cytoskeletal dynamics, 
RhoGAPs are bound to influence these processes as well by the virtue of their 
control of RhoGTPases.  RLIP76, a Rac/Cdc42-GAP domain containing 
protein is important for RalGTPase mediated endocytosis, by acting as a link 
between growth factor receptor signalling and protein involved in endocytosis 
[Jullien-Flores et al., 2000]. BPGAP1, a novel GAP identified by our group 
showed that upon interaction with EEN/endophilin II activate ERK signalling 
via EGFR mediated endocytosis [Lua and Low, 2005]. It was also shown that 
the BNIP-2 and Cdc42GAP Homology (BCH) domain of BPGAP1, via its 
interaction with K-Ras induces PC12 cell differentiation [Ravichandran and 
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Low, 2013]. BPGAP1 promotes cell migration through a concerted action of 
its BCH, proline-rich and GAP domains as well as its binding with Cortactin, 
a cortical actin binding protein, leading to its translocation to cell periphery 
[Lua and Low, 2004; Shang et al., 2003]. p190RhoGAP has been seen to play 
a role in axon outgrowth, guidance and fasciculation, and neuronal 
morphogenesis. Also, p190B RhoGAP, one of the p190RhoGAP isoforms 
affects cell growth and differentiation, an effect seen by the reduction in size 
of mice thymus in the absence of p190B. MgcRacGAP mediated down-
regulation of Cdc42 also affects cell growth by affecting the spindle formation 
in cytokinesis [Moon and Zheng, 2003]. DLC1 also affects cell migration and 
brings about change in cell morphology by reducing the stress fiber formation 
via its activity on RhoA [Kim et al., 2008].  
 
1.2.6.3 RhoGAPs: Tumorigenesis 
 
RhoGTPases’ role in tumorigenesis and progression, and 
RhoGAPs’role in suppression of RhoGTPases, logically places RhoGAPs 
under the class of tumor suppressors. Indeed, RhoGAPs have been seen to be 
down-regulated or deleted in various cancers. Our protein of interest, DLC1 
was seen to deregulated in many tumors as well as the gene was deleted in 
more than 40% of Hepatocellular carcinoma (HCC) in which it was initially 
identified. Since then, work done has found loss of DLC1 correlated to various 
cancers other than HCC [Lahoz and Hall, 2008]. One of the first identified 
RhoGAPs BCR is seen to undergo chromosomal translocation to form a fusion 
protein with Abl, an oncogene in leukaemia. GRAF, an FAK-associated 
RhoGAP, has also been identified in leukaemia undergoing translocation. 
With cancers showing a loss of RhoGAPs, experiments were done to see if the 
overexpression of these proteins could reverse the effect. True to the expected 
role as tumor suppressors, overexpression of p190RhoGAP repressed Ras-
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induced transformation in NIH3T3 fibroblast cells [Moon and Zheng, 2003].  
p85-alpha subunit of PI3-Kinase has a RhoGAP domain which is seen to 
suppress metastasis in ovarian cancers.  
 
1.3  Deleted in Liver Cancer-1: A RhoGAP and a Tumor suppressor  
 
Of approximately 70 GAPs that are expressed by the human genome, 
only a few of these are seen to localize at the focal adhesions. Deleted in Liver 
Cancer1 (DLC1) is one such RhoGAP. DLC-1 transcript is 3850bp and 
translates to about a 125 kDa protein. It was identified in a representative 
difference analysis (RDA) screen as being absent in Hepatocellular Carcinoma 
(HCC) tissues as compared to being ubiquitously present in the non-cancerous 
tissues [Yuan et al., 1998].  
DLC1 has since then been characterized as a bona fide tumour 
suppressor. 8p21.3-22, location of DLC1 on the chromosome, is a region that 
is subjected to high frequency of Loss of Heterozygosity (LOH). Though 
initially identified to be deleted in HCC, this loss now extends to various 
cancers including prostate, lung, breast, colon, bladder and head and neck 
[Lahoz and Hall, 2008]. mRNA down-regulation of DLC1 is a key feature in 
many of these cancers and this can be attributed to epigenetic silencing 
mechanisms like DNA hypermethylation and histone acetylation apart from 
the frequently observed LOH [Durkin et al., 2007a]. Recently, somatic 
mutations of DLC1 have also been identified in prostate cancer. Initial 
experiments demonstrated DLC1’s ability to inhibit tumorigenicity in nude 
mice and cell growth, when carcinoma cell lines lacking DLC1 were 
transfected with DLC1 cDNA. [Ng et al., 2000; Yuan et al., 2004; Zhou et al., 
2004]. Also, studies done in breast cancer lines indicated that the metastatic 
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potential could be correlated with the expression levels of DLC1 [Goodison et 
al., 2005].  
DLC1 is a GTPase-activating protein (GAP) protein with in vitro 
activity for the small GTPases RhoA, RhoB, and RhoC, and to a lesser extent 
Cdc42   [Healy et al., 2008; Wong et al., 2003]. It is a multi-domain protein 
that contains an amino-terminal sterile α motif (SAM), a RhoGAP domain, a 
serine-rich unstructured region between the SAM and the RhoGAP domain 
and a StAR (steroidogenic acute regulatory)-related lipid transfer (START) 
domain at its carboxy-terminus. It belongs to a family of protein which contain 
the SAM-RhoGAP-START domain architecture [Durkin et al., 2007b]. DLC2 
and DLC3 belong to this family. The genes encoding these three proteins are 
paralogues of each other, which arose by gene duplication [Durkin et al., 
2007a]. 
1.3.1. DLC1 Domains and their functions: 
 
1.3.1.1 SAM domain 
 
SAM domain at the N-terminal of DLC1 is about 70 amino acids. The 
human genome contains about 200 proteins that contain the SAM-domain 
[Qiao and Bowie, 2005]. This motif has been seen to occur in many other 




Fig 1.4: DLC1 domain architecture and its interactome (Courtesy: Shelly 
Kaushik) 
 
folds in this domain are similar across the different range of proteins. SAM 
domain has a globular tertiary structure formed by folding of amino acids into 
5 alpha helices, encasing a hydrophobic core. Despite the structural similarity 
in the proteins, proteins containing SAM domain have a global cellular 
distribution with varied interacting partners, giving the proteins diverse and 
unique functions [Kim and Bowie, 2003; Qiao and Bowie, 2005]. These are 
mainly involved in protein-protein interactions with SAM domain-containing 
proteins, which may be homo- and heterotypic in nature, as well as, with other 
proteins which do not have the SAM domain, leading to the formation of 
dimers, oligomers and polymers [Durkin et al., 2007b]. Apart from this they 
have also been shown to interact with lipids, like in the case of SAM domain 
of p73, a p53 homologue  and RNA, in the case of Smaug and its homologue, 
which are translational repressors [Kim and Bowie, 2003]. 
So far, the work done on SAM domain of DLC1 has shown that it 
might not be necessary for DLC1’s GAP-dependent functions. Transfection of 
SAM domain alone was unable to induce morphological changes in the cell, 
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namely cell rounding, bring about the dissolution of the actin stress fibres or 
inhibit colony forming ability of HCC cells, which are characteristic of DLC1 
expression [Wong et al., 2005]. Also, SAM domain alone does not localize to 
the focal adhesion [Kim et al., 2008]. This observation was complemented by 
a previous observation which showed that over-expression of a DLC1 mutant 
lacking SAM domain, exhibited behaviour similar to that of wild-type DLC1. 
This confirms that SAM domain is not necessary for DLC1s GAP-mediated 
function or its tumor suppressive activity [Wong et al., 2005]. Work done by 
Kim et al. 2008, shows that SAM domain might possibly be a negative 
regulator of DLC1 GAP activity, by the means of auto-inhibition. Introducing 
DLC1 lacking SAM domain showed a reduction in the directionality of cell 
movement and induced a more drastic morphological change in the cells when 
compared to the wild type DLC1, as this mutant probably has constitutively 
active GAP function.  
Recently, eukaryotic elongation factor 1A1 (EF1A1) was identified as 
a potential binding partner of DLC1s SAM domain. Upon growth factor 
stimulation, EF1A1 interacts with DLC1 leading to its localization at the 
membrane periphery and ruffles, which regulates cell migration [Zhong et al., 
2009]. Migratory ability of breast cancer cells were also seen to be affected by 
the interaction of the SAM domain with PTEN (phosphatase and tensin 
homologue), a tumor suppressor [Heering et al., 2009].  
An NMR study done to resolve the structure of DLC1 SAM revealed a 
surprising fold in the SAM domain. It showed that DLC1 has a monomeric 
four α-helical structure unlike the five α-helical bundles usually seen in SAM 
domains of other proteins. This is similar to the structure of DLC2 SAM 





1.3.1.2 RhoGAP domain  
 
RhoGAP domain of the DLC family of proteins is the most conserved 
domain amongst them, with about 70% sequence identity [Durkin et al., 
2007b]. This is the functional domain of DLC family, which enhances the 
intrinsic GTPase activity of Rho proteins, thus regulating their cycling 
between the active and the inactive state. DLCs have a conserved “arginine 
finger” arginine residues, namely R677 and R718 in humans, which are vital 
for the RhoGAP function. The loop containing this residue lends a positive 
charge to the catalytic site of Rho, which allows the glutamine residue present 
there to be stabilized in a proper conformation [Li and Zhang, 2004]. This 
conformation makes it susceptible to nucleophilic attack by water molecule 
leading to hydrolysis of the γ-phosphate of the GTP [Bos et al., 2007].  
It has been seen that DLC1 has in vitro GAP activity which is specific 
for RhoA, RhoB, RhoC and to a lesser extent towards Cdc42 and does not 
show any effect on Rac1 [Healy et al., 2008; Wong et al., 2003]. This was 
consistent with the observation that p122RhoGAP also showed in vitro GAP 
activity for RhoA but not Rac1 [Sekimata et al., 1999]. The in vitro and in vivo 
substrate specificity of the various GAPs differ from each other [Moon and 
Zheng, 2003]. Even though it was not conclusively said, data showed that 
overexpression of DLC1 and its rat homologue p122RhoGAP results in the 
loss of actin stress fibers, which is due to the possible down-regulation of 
RhoA [Sekimata et al., 1999; Wong et al., 2005]. This is confirmed by 
overexpression of constitutively active RhoA reverses the loss of actin stress 
fibers brought about by p122RhoGAP [Sekimata et al., 1999]. Introduction of 
GAP-inactive mutants of DLC1 and p122RhoGAP or mutants lacking the 
GAP domain had no effect on the cellular morphology or the actin 
cytoskeleton [Sekimata et al., 1999; Wong et al., 2005]. Also, active RhoA at 
the leading edge of protrusions of migrating cells was drastically reduced upon 
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ectopic expression of DLC1 [Healy et al., 2008]. Furthermore, RhoA 
knockdown in two independent experiments with murine hematomas which 
lacked DLC1resulted in suppressed tumor growth proved that hyperactivation 
of RhoA upon loss of DLC1 was a key factor in tumorigenesis [Xue et al., 
2008].  
The effect of DLC1 GAP domain on RhoA activation was confirmed 
by the use of RhoA-Raichu biosensor. It was seen that wild-type DLC1 but not 
the GAP-negative mutant was responsible for a decrease in the emission ratio 
of the biosensor during fluorescence resonance energy transfer (FRET), which 
is in response to the hydrolysis of RhoA-GTP to RhoA-GDP [Holeiter et al., 
2008]. Also, RhoA mediated change in the actin cytoskeleton was affected by 
expression of wild-type DLC1 and not GAP-inactive mutants. Hence the 
rounding up of cells, cortical retraction and other cytoskeletal changes can be 
attributed to the GAP activity of DLC1 [Wong et al., 2005; Yuan et al., 2007].  
Actomyosin contractility is controlled by phosphorylation of myosin light 
chain (MLC2) by Rho Kinase (ROCK), a RhoA effector. Wong et al (2008) 
showed that the deregulation of this pathway leading to the dissolution of the 
stress fibers and disassembly of the focal adhesions was a GAP dependent 
function of DLC1. The Rho/ROCK/MLC2 regulation by DLC1 GAP function 
was confirmed with the increase in local RhoA activation, which lead to the 
strengthening of the focal adhesions as well as the actomyosin contractility, 
upon DLC1 displacement from the focal adhesions [Wong et al., 2008]. As a 
consequence of DLC1 mediated decrease in actomyosin contractility, HCC 
cells’ capability to migrate and metastasize was greatly impaired [Kim et al., 
2008]. Another example of DLC1s specificity to Rho is the inability of DLC1 
to affect the formation of actin protrusions via Rac1 dependent pathway 
forming actin-related protein 2/3 (Arp 2/3) actin nucleation complex [Kim et 
al., 2008]. Evidence of direct modification of GAP domain of DLC1 was seen 
recently when S807 was identified as a target for Protein Kinase D (PKD). 
The authors showed that a phospho-defective mutant S807A inhibited colony 
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formation more potently that the wild type DLC1, suggesting that 
phosphorylation of these residues acts to negatively regulate DLC1s tumor 
suppressive function [Scholz et al., 2011].   
Small GTPases, Ras and Rho, crosstalk has been a point of interest for 
a long time as both the pathways play significant roles in carcinogenesis. One 
such point where the pathways seem to come together was seen when 
p120RasGAP was identified as an interacting partner for the GAP domain of 
DLC1 [Yang et al., 2009b]. This interaction upon overexpression in colon 
carcinoma cells completely nullified the tumor suppressive function of DLC1 
by inhibiting its GAP activity and thus increasing active RhoA levels at the 
focal adhesions [Yang et al., 2009b].  
Although, there are reports that show that GAP-negative mutant of 
DLC1 is sufficient to inactivate DLC1s tumor suppressive functions, recent 
findings suggest otherwise. DLC1-K714E was seen to lose its ability to 
suppress colony forming capabilities of HCC cell [Wong et al., 2005].  At the 
same time, it was seen that formation of stress fibers could not be suppressed 
alone by the GAP domain of DLC1 and probably requires others domains or 
the immediate regions that flank the GAP domain at the C- and N-terminal 
[Wong et al., 2005]. Healy et al (2007) reported that DLC1s tumor suppressive 
functions were mediated in both GAP-dependent and GAP-independent 
fashion, leading to the conclusion that the DLC1 GAP activity is important but 
not sufficient to carry out the tumor suppression.  
 
1.3.1.3 START domain  
 
This domain forms the C-terminus of DLC. These domains are 
typically found in lipid metabolizing proteins or lipid transfer proteins, in 
which they form a hydrophobic pocket to capture the lipid molecule for 
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transport between membranes [Ponting and Aravind, 1999]. Initially 
indentified as a domain being conserved in two lipid-binding proteins namely, 
steroidogenic acute regulatory protein (STAR) and metastatic lymph node 64 
(MLN64) at their C-termini, now about 15 human proteins have been seen to 
contain this 200-210 amino acid containing domain, which can be divided into 
six subfamilies [Alpy and Tomasetto, 2005].  
Crystal structures solved thus far show that START domains contain a 
conserved fold forming a tunnel-like structure consisting of  9 β-strands giving 
rise to a β-sheet which is capped at the C- and N- termini by α-helices [Alpy 
and Tomasetto, 2005]. This β-sheet tunnel is large enough to fit in lipophilic 
molecules such as cholesterol as seen in the case of STAR and MLN64. The 
C-terminal α-helix acts as a lid for this structure allowing the entry of the 
molecules [Soccio and Breslow, 2003]. One would expect with such 
conserved structures, that the proteins containing these domains would have 
similar interacting partners. But these proteins not only have varied binding 
partners but also are very specific in their interactions for example STARD5 
binds only 25-hydroxycholesterol whereas STARD1/MLN64/STARD5 binds 
only cholesterol [Alpy and Tomasetto, 2005].  This binding property is 
indicative of the fact that these proteins are irreplaceable in their functions. 
The ability of START-domain contain protein to bind lipids make them key 
players in cellular mechanisms which includes trafficking, metabolism, 
regulation of transcription and signal transduction involving lipids.   In fact, 
START domain-containing proteins are involved in various lipid-related 
cellular processes, including lipid trafficking, lipid metabolism, lipid-
modulated signal transduction and transcriptional regulation.  
In a START domain containing proteins review by Alpy and 
Tomasetto (2005), they have summarized various mechanisms by which these 
proteins play a role in the cellular processes by means of acting as an interface 
for lipid-sensing or lipid transfer. MLN64 is an example for a protein that via 
its lipid-transferring capabilities plays a role in cholesterol homeostasis by 
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transporting endosomal cholesterol. STARD6 through lipid-interaction, 
regulates transcription during the process of spermatogenesis. On the other 
hand, START domain STARD11 plays a role in signal transduction by 
regulating its own kinase activity towards the Goodpasture antigen in the 
Goodpasture disease. STARD10 is seen to localize to the sperm flagellum and 
is a transporter for phosphatidylcholine (PC) and phosphatidylethanolamine. It 
is suggested that STARD10 might be involved in the energy metabolism in the 
sperm flagellum by providing PC as potential substrate.  
Despite the vast knowledge about the various START domains, the 
role of DLC1s START domain still remains to be elucidated to a great extent. 
There has been no evidence of lipid-binding property of START domain of 
DLC1. Sequence alignment with START domains of other proteins show 
similarity with the regions flanking the PC binding site as seen in the PC-
transfer protein, which points towards the possibility of DLC1 binding PC and 
other similar lipids [Ponting and Aravind, 1999]. The rat homologue of DLC1, 
p122RhoGAP, is seen to interact with phospholipase C delta 1 (PLC-δ1) 
leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate [PtdIns 
(4,5)P2] which leads to the formation of inositol 1,4,5-triphosphate, finally 
releasing Ca
2+
 from the intracellular stores [Homma and Emori, 1995]. This 
interaction is carried out via its C-terminus encompassing both the START 
and the GAP domain [Sekimata et al., 1999]. p122RhoGAP is seen to localize 
to the plasma membrane of the caveolae, binding to caveolin there, potentially 
through the lipid-binding property of the START domain [Yamaga et al., 
2004]. Recent work has showed that START domain is important but not 
sufficient in itself for carrying out DLC1s tumor suppressive. START domain 
is not necessary for the focal adhesion targeting function of DLC1 [Kim et al., 
2008], but loss of this domain affects DLC1s ability in inhibiting the colony 
forming nature of HCC cells as well inhibition of stress fiber formation 
leading to morphological changes in the cell [Wong et al., 2005]. Another 
recent study showed that the START domain of DLC1 is necessary for DLC1 
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interaction and localization with caveolin-1. Without the presence of the 
START domain, DLC1 failed to interact with caveolin-1 and this directly 
affected DLC1s ability to suppress neoplastic growth [Du et al., 2012].  
Though there is a lack of knowledge, we can extrapolate that the 
START domain might help in determining the subcellular localization of DLC 
in the cell and might also be involved in regulating its GAP function, like in 
the case of other RhoGAP proteins such as Cdc42GAP which contains the 
Sec14 domain [Alpy and Tomasetto, 2005; Moon and Zheng, 2003].  
 
1.3.1.4 Serine-rich region  
 
The region between SAM and GAP domains is an unstructured region 
whose tertiary structure is unknown and shows the least sequence conservation 
amongst the three DLCs, showing only short stretches of high similarity 
separated by large gaps and insertions [Durkin et al., 2007a]. This region is 
rich in amino acids S, P, Q, E and K, which are known to be enriched in 
unstructured proteins as they disrupt an orderly arrangement. Also, it lacks 
hydrophobic amino acids, which potentially give proteins a globular structure 
by forming the core. The serine-rich region is interspersed with proline-rich 
regions, thereby allowing binding to proline recognition motifs like the WW 
motif and the SH3 motif [Durkin et al., 2007b]. It also contains LD motif 
(LDXLLXXL) that is seen in paxillin and its binding partners [Brown et al., 
1998]. The unstructured region gives the protein flexibility, thereby allowing 
interaction with multiple proteins which could aid in spatial and temporal 
regulation as well as increasing DLC1s susceptibility to proteolysis thereby by 
controlling the protein turnover. These regions are also hot spots for post-
translational modifications like phosphorylation especially by serine/threonine 
kinases, which regulate the activity of the protein itself [Durkin et al., 2007b]. 
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One such finding was the S567 phosphorylation by Akt, which negatively 
regulates DLC1s GAP-dependent suppression of tumorigenesis and metastasis 
[Ko et al., 2010b].  
DLC1 is known to cause morphological change in cells [Sekimata et 
al., 1999]. This function of DLC1 which led to rounding up of cells was 
attributed to its localization to focal adhesions and not only its GAP activity 
[Kawai et al., 2009a]. There have been studies that show DLC1 interaction 
with a group of proteins called Tensins which consist of tensin1, tensin2, 
tensin3 and cten and are important for DLC1s localization to focal adhesions 
[Liao et al., 2007; Qian et al., 2007; Yam et al., 2006]. Tensins have a highly 
conserved C-terminus, which consist of a Src-homology 2 (SH2) domain and a 
phosphotyrosine binding (PTB) domain [Lo and S., 2004]. A yeast two hybrid 
screening of human liver cDNA revealed Tensin 2 as a novel interacting 
partner and they were seen to colocalize to vinculin-associated focal adhesions 
via the phosphotyrosine-binding domain (PTB) on Tensin2 [Chan et al., 2009; 
Yam et al., 2006]. DLC1 interacts with cten via the SH2 domain in a 
phosphotyrosine independent manner although requiring the sites S440 and 
Y442 and the mutation of these sites causes DLC1 to be cytoplasmic diffused 
[Liao et al., 2007; Qian et al., 2007].  The two sites which were seen to be 
important for cten interaction with DLC1 were also found to be necessary for 
DLC1 interaction with the PTB and SH2 domain of tensin1 [Qian et al., 2007]. 
Independently conducted studies have shown that DLC1 mutants which lose 
their binding ability with tensin do not localize to focal adhesion, also tend to 
lose their ability to suppress colony formation. This indicates that DLC1 
localization to focal adhesions is necessary for its GAP activity [Liao et al., 
2007; Qian et al., 2007]. Region between 359-397 amino acids on DLC1, 
termed as Focal Adhesion Targeting (FAT) region mediates its binding to the 
PTB domain of tensin, which was later narrowed down to amino acids 375-
385 [Kawai et al., 2010; Kawai et al., 2004]. In addition to localization at the 
focal adhesions, tensin2 and DLC1 were found to be in a complex with 
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caveolin-1 at the caveolae of hepatocytes and were involved in the Ras 
signalling inhibition [Yam et al., 2006]. LD-like motif consisting of amino 
acids 469-476 in DLC1 is necessary for its binding to two molecules namely, 
talin and focal adhesion kinase (FAK). This motif is homologous to the LD 
motif seen in paxillin. DLC1 mutants lacking residues from this region or 
carrying amino acid substitutions were seen not to be able to bind either of the 
molecules. Though, both FAK and talin were targeted to the same region on 
DLC1, their binding was independent of each other. Mutants lacking the 
ability to bind talin and FAK though did not show any suppressed GAP 
activity, they were less potent in tumor suppression. This binding was also 
seen to be required for DLC1s focal adhesion localization [Li et al., 2011].  
 The serine-rich region of DLC1 contains a bipartite nuclear localizing 
signal sequence which lies within amino acids 415 – 430 the regulatory region 
for which is located within the region of amino acids 209 – 291, which 
controls the duration of nuclear residency of DLC1 as well as its stability 
[Yuan et al., 2007]. DLC1 also undergoes a phosphorylation-dependent 
interaction with 14-3-3 adaptor proteins. This interaction, stimulated by 
protein kinase C and protein kinase D, inhibits the nucleocytoplasmic shuttling 
of DLC1 and its cellular functions by blocking its nuclear localization signal 
sequence [Scholz et al., 2008]. Another region between amino acid 600-700 
was identified as being important for the purpose nuclear localization of 
DLC1. It was seen that in the fusion protein variant of DLC1 (NLS-DLC1) 
which predominantly localizes to the nucleus, the tumor suppression mediated 
by DLC1 was greatly reduced as seen by the failure to suppress colony 
formation and formation of stress fibers in SMMC-7721 cells. In vivo it was 
seen that nude mice injected with the NLS-DLC1 expressing hepatoblasts, 
these cells formed tumors much more effectively as compared to the wild-type 
DLC1 [Chan et al., 2011]. DLC1 contains 5 conserved PEST sequences in its 
serine-rich region, which increases its stability, without which DLC1 was seen 
to be susceptible to degradation by the 26S proteasome [Luo et al., 2011].   
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Protein Kinase A (PKA) mediates the phosphorylation of S431 and 
S549. It was seen that the phosphorylation of S549 was important for the event 
of S431 phosphorylation. The importance of S549 phosphorylation is not 
limited to that but is also seen to be required for DLC1s tumor suppressive 
functions as S549A fails to inhibit colony formation is SMMC7721 cells. It 
also had an effect on the migratory and invasive properties of hepatoma cells. 
Phosphorylation of this residue also induced dimerization of DLC1, in turn 
enhancing its RhoGAP activity [Ko et al., 2013]. α-catenin was identified as 
novel binding partner for DLC1. This requires amino acids 340-345 in the 
serin-rich region and the C-terminus of α-catenin. This binding led to the 
accumulation of the complex at the plasma membrane and stabilized the 
Adherent Junctions (AJ). This was carried out by reduction in the active RhoA 
levels, which also increased the mobility of E-cadherin as well as affected the 
actin cytoskeleton. In metastatic prostate cancer cells it was seen that this 
association led to a more potent DLC1 activity [Tripathi et al., 2012]. 
Apart from protein based-interactions, a study revealed that adjacent to 
the GAP domain of DLC1, there is highly conserved region consisting mainly 
of basic amino acids termed as Poly Basic Region (PBR), which facilitates the 
binding of DLC1 with phosphatidylinositol-4,5-bisphosphate or PI(4,5)P2.  
This interaction greatly enhances the GAP activity of DLC1, leading to 
inactivation of Rho signalling [Erlmann et al., 2009]. It has also been shown 
that Erk5 expression in Src-transformed cells, increases DLC1 expression, 
which in turn leads to decrease in RhoA-mediated signalling and leads to 
podosome formation [Schramp et al., 2008].  
The isolated GAP region (652-798) alone does not have any functions, 
indicating that there are other regions on DLC1 that control the activity of this 
protein [Kim et al., 2008]. It has already been shown that binding of proteins 
such as tensin to the FAT region is essential for DLC1s function as a tumor 
suppressor  [Liao et al., 2007]. A study conducted to identify mutations 
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present in this region in the genomic DNA of cancer patients’ revealed 
mutations, namely, T301K and S308I. Though these mutations do not impair 
the focal adhesion targeting of DLC1, they affect GAP function of DLC1 as 
seen by the inability of these mutations to prevent colony formation [Liao et 
al., 2008]. DLC1s interaction with a pro-inflammatory protein S100A10 via 7 
residues in the serine-rich region from amino acids 348-354 lead to 
degradation of S100A10, which had an inhibitory effect on the invasiveness, 
col ony forming ability and cell migration of A549 cells in a GAP-independent 
manner [Yang et al., 2011].  
 
1.3.2 RhoGAP-independent functions of DLC1  
 
DLC1, a multi-domain protein, has three known functional domains so 
far and an unstructured region, which has been implicated as being important 
for regulating DLC1s function. Out of the three domains, GAP is the most 
studied domain. Evidence suggests that RhoGAP activity of DLC1 is 
important but not exclusively responsible for the tumor suppression is shown 
by the ability of GAP-inactive mutant to inhibit to a great extent, the in vitro 
growth and invasive property of NSCLC [Healy et al., 2008]. One such 
finding was that SAM domain alone is seen to have an effect on cell migration 
by its specificity to bind to Elongation Factor1A1 (EF1A1) and localize to 
membrane periphery and ruffles [Zhong et al., 2009]. Other than protein 
synthesis, EF1A1 has been implicated in various aspects of cytoskeletal 
organization and cell growth.  Also, GAP-inactive mutant of DLC1, which had 
tensin-binding residues still intact had the capability of inhibiting cell 
migration comparable to the DLC1 mutants that had lost the ability to bind 
tensins but retained its GAP activity [Qian et al., 2007], though not to the 
extent of wild-type protein. This observation implies that, unlike previous 
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belief, the tensin-binding ability and RhoGAP function of DLC1 might 
independently contribute to DLC1s role in tumor suppression. The most recent 
work showing DLC1s GAP-independent function was the binding of DLC1 to 
a cell surface plasminogen receptor, S100A10. Upon DLC1 binding, S100A10 
becomes susceptible to degradation via the ubiquitin pathway, leading to the 
attenuation of the plasminogen activation as well as inhibiting cell migration 
and invasion. This effect was the same in both wild-type DLC1 as well as 
GAP-inactive DLC1 [Yang et al., 2011].  
Given the ability of DLC1 to function in both GAP-dependent and –
independent manner, it is no surprise that compared to the very many 
RhoGAPs, it is seen to be more frequently affected in cancers.   
 
1.3.3 DLC family- Functions: 
 
 The family to which DLC1 belongs consists of two other members 
namely, DLC2 and DLC3. The genes encoding the three proteins arose by 
gene duplication and are paralogues of each other. DLC1 and DLC2 have 58% 
similarity, whereas DLC1 has only 44% similarity to DLC3. DLC2 and DLC3 
are 52% similar.  
DLC2 and DLC3 have been seen to localize to focal adhesions 
associated with vinculin, through possibly their interactions with tensin-family 
of proteins [Kawai et al., 2007; Kawai et al., 2009b]. Work done on the DLC 
family of proteins show that DLC2 displaces endogenous DLC1 from the 
focal adhesions, by competing with its focal adhesion targeting region, 
suggesting common mechanisms by which they target focal adhesions [Kawai 
et al., 2009b].  
 DLC2, like DLC1, causes rounding up of cells and disruption in the 
actin cytoskeletal structures by inhibiting RhoA activity, a function which is 
dependent on its GAP activity [Leung, 2005]. DLC2 has also been seen to 
localize with mitochondrial markers and were seen in lipid droplet-like 
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structures and the START domain was necessary for both these localizations 
[Ng et al., 2006]. Studies have shown that DLC2, unlike DLC1 is not 
embryonic lethal [Yau et al., 2009]. Also, DLC1s downstream effects include 
reduction in the phosphorylated states of paxillin and FAK [Kim et al., 2007], 
whereas as DLC2 has been seen to effect only the phosphorylation status of 
paxillin and not FAK. DLC2 regulates cell cycle via inhibition of Raf-1-
ERK1/2-p70S6K pathway instead of modulating its effect via the CDK 
inhibitors [Leung et al., 2010].  
The knowledge on DLC3 is much less as compared to DLC2. It has 
been seen that DLC3, like other DLCs, inhibits tumor growth [Durkin et al., 
2007a]. DLC3 also binds to the SH2 and PTB domains of tensins [Qian et al., 
2007].  
 DLC gene family are evolutionarily conserved. Initially identified in 
mouse (ARHGAP7 or STARD12) and rat (p122RhoGAP), they are now seen 
to have orthologues in other vertebrates namely Canis lupus (dog), Gallus 
gallus (chicken),  Xenopus tropicalis (frog), Lagocephalus lagocephalus 
(puffer fish), Pan troglodytes (chimpanzee) and invertebrates such as 
Drosophila and C. elegans [Durkin et al., 2007b]. 
Initially discovered as a binding partner for phospholipase C-1 (PLC-
1), rat p122RhoGAP protein is 93% identical to human DLC1. The 
expression of this rat orthologue is very similar to that of humans [Durkin et 
al., 2007b]. The GAP domain of this protein functions synergistically with 
PLC-1, inhibiting the activation of RhoA causing cell rounding via the loss 
of actin stress fibres as well as focal adhesions [Sekimata et al., 1999]. Unlike 
in humans, p122RhoGAP leads to the release of intracellular calcium and 
activates protein kinase C, by hydrolysing phosphatidylinositol (4, 5)-
bisphosphate (PIP2) leading to the formation of second messengers inositol 
triphosphate and diacylglycerol [Healy et al., 2008; Homma and Emori, 1995].  
The crossveinless-c (cv-c) gene in Drosophila encodes the protein 
homologous to the human DLC1. Its role was indispensible during 
35 
 
morphogenesis. It was seen to be necessary for regulation of RhoGTPase 
leading to cytoskeletal remodelling [Denholm et al., 2005] as well as for 
regulating tubulogenesis [Durkin et al., 2007b]. The ability of the human 
DLC1 to negatively regulate RhoA leading to the actin cytoskeleton 
reorganization is similar to that seen in both the rat and the Drosophila 
orthologues [Kawai et al., 2004; Sato et al., 2010].  
 
 
1.4  Focal adhesion kinase 
 
 Focal adhesion kinase (FAK), in 1992, was independently identified by 
Steve Hanks, Jun-Lin Guan and Michael Schaller. It was initially identified as 
a tyrosine kinase which gets highly phosphorylated upon formation of 
intergrin-associated adhesion sites in cells and was seen to be a substrate of 
viral oncogene, Src [Guan and Shalloway, 1992; Hanks et al., 1992; Schaller 
et al., 1992]. FAK is also referred to as protein tyrosine kinase2 (PTK2) and is 
found in chromosome 8q24term [Mitra et al., 2005].  It is almost ubiquitously 
expressed and is a well conserved all the way from lower eukaryotes like 
Drosophila and zebrafish to mammals [Parsons, 2003]. FAK along with 
PYK2 are the two members of FAK family of non-receptor protein tyrosine 
kinases. They share similar structure and functions but also have other distinct 
functional properties.  Both these proteins not only play an important role in 
the signalling cascade as kinases but also behave as scaffolds to allow 
assembly of the signalling complexes. Activation of FAK occurs through 
mainly integrin-mediated signalling and to some degree by growth factor 
receptor and cytokine receptor activation and mechanical stimulation. Focal 
adhesion Kinase (FAK) plays a role in three major cellular processes, namely, 
cell survival, cell proliferation and cell motility [Hall et al., 2011].  
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1.4.1  FAK: Structure 
 
FAK is a 125kDa multi-domain protein with a kinase domain and two 
non-catalytic domains. The N-terminal domain of FAK shows sequence 
similarity to the family of proteins containing the FERM (erythrocyte band 
four.1-ezrin-radixin-moesin) domain. The C-terminal domain has focal 
adhesion targeting (FAT) sequences and the central domain is the kinase 
domain which is proline rich. In general, members of this family link 
transmembrane glycoproteins to the actin cytoskeleton [Mitra et al., 2005; 




Fig 1.5: FAK domain structure and binding partners [Mitra et al., 2005] 
 
1.4.1.1  FERM domain: 
 
The function of the N-terminal domain of FAK is not completely 
understood. The FERM domain of FAK acts as the domain of interaction with 
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the receptor tyrosine kinases such as EGFR and PDGFR and allows for further 
activation of downstream signalling molecules [Sieg et al., 2000]. This domain 
mediates binding of FAK to β-integrin, which is necessary for activation of 
FAK itself as well as strengthening of integrin-associated adhesions [Mitra et 
al., 2005]. FAK is known to activate other non-receptor tyrosine kinases such 
as Etk which requires the binding of the FERM domain of FAK to the PH 
domain of Etk [Chen et al., 2001]. Furthermore adaptor proteins associated 
with actin like ezrin lead to an increased FAK activation by binding to the 
FERM domain, in an integrin-independent manner [Mitra et al., 2005]. This 
domain is also subjected to posttranslational modification, namely 
sumoylation (addition of a small ubiquitin-related modifier (SUMO)), which 
could be the possible stimulus for FAK accumulation in the nucleus, as is with 
other proteins. Upon sumoylation, FAK shows increased catalytic activity, 
indicating a potential signalling link between the focal complexes and the 
nucleus [Kadare et al., 2003]. So, the FERM domain may act to regulate the 
catalytic function of FAK by interaction with other proteins or by direct 
modification as well as link FAK to integrin- and growth factor receptor-
linked signalling.  
 
1.4.1.2  C-Terminal domain: 
 
 This domain is important for protein-protein interactions. It also 
contains the focal adhesion targeting (FAT) region that is about 100 amino 
acids long and is necessary for FAK localization to the focal adhesions. The 
FAT domain is similar to those in other focal adhesion localizing proteins such 
as Cas, vinculin etc. It consists of a four-helix bundle structure. The FAT 
domain also mediates the binding between FAK and paxillin [Hayashi et al., 
2002]. There is a hydrophobic patch on either side of the domain which is 
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supposed to interact with the LD motif on paxillin. Paxillin acts as the docking 
partner for FAK at the focal adhesions as it binds to the cytoplasmic domain of 
the intergrin present in them [Hall et al., 2011; Hayashi et al., 2002]. 
Surprisingly though, mutants of FAK that fail to bind paxillin were still seen 
to target to the focal adhesions, suggesting that there are other possible 
mechanisms of FAK targeting to adhesion complexes. FAK is also seen to 
associate with the focal adhesions via its interaction with another focal 
adhesion protein, Talin [Cooley et al., 2000]. It was recently shown that FAK 
through its FAT region interacts with DLC1s LD-like motif. This interaction 
was important for DLC1 localization to the focal adhesions [Li et al., 2011]. 
This domain apart from the FAT region also consists of two proline-
rich regions which allow interactions with SH3 domain containing proteins. 
One such example is the binding of p130Cas with FAK which is seen to be 
important for cell migration. This region is also necessary for FAK interaction 
with RhoGTPase regulators such as GRAF and ASAP1, hence providing a 
link between the assembly of focal adhesions and cytoskeletal dynamics 
[Mitra et al., 2005]. 
Also, a region called the FRNK (FAK-related-non-kinase) present in 
the C-terminal is expressed independently in vivo and functions possibly as a 
negative regulator of the catalytic activity of FAK. The expression of FRNK is 
controlled by transcriptional elements found between the last exon of the 
kinase domain and the first exon of the C-terminal domain. Over-expression of 
FRNK inhibits cell spreading and migration [Hall et al., 2011].  
 
1.4.1.3 Kinase domain: 
 
FAK kinase domain is highly similar to the kinase domains of other 
non-receptor tyrosine kinases as well as receptor tyrosine kinase. A feature 
unique to this kinase domain is the presence of a disulphide bond in the 
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terminal lobe of this domain observed via crystallographic studies. Presence of 
this bond could be possibly important for the kinase function [Nowakowski et 
al., 2002]. FAK gets phosphorylated at Tyr397 present in the kinase domain 
upon integrin clustering. It has been recently shown that FAK undergoes 
dimerization leading to intermolecular phosphorylation of Tyr397 [Katz et al., 
2002]. This causes an increase in FAK’s catalytic activity and subsequently 
leads to the phosphorylation of focal adhesion-associated proteins at the Tyr 
residue. Activation of this residue is also important for phosphorylation of 
Tyr576 and Tyr577, two highly conserved residues in the catalytic loop of the 
kinase domain, for the maximal FAK activity signalling the start of the 
downstream cascade [Mitra et al., 2005].  
 
1.4.2  FAK activation and regulation:  
 
 The activation of FAK is started off by auto-phosphorylation of 
Tyr397 in cis or trans, which creates a binding motif for SH2 domain-
containing proteins [Mitra et al., 2005]. This occurs once FAK localizes to the 
integrin-associated focal complexes via the FAT region at the C-terminal 
domain. Phosphorylation of this residue promotes binding of Src, causing a 
conformational activation of Src. Activation of Src leads to 
transphosphorylation of FAK at Tyr 576 and Tyr577, which lie in the 
activation loop of the kinase domain. This event is important for the maximal 
activation of FAK [Hanks et al., 2003].  
FAK is regulated by conformational changes and protein-protein 
interactions. The kinase domain has a unique disulphide bond, which might 
regulate FAK activity through conformational changes [Parsons, 2003]. 
Binding of FAK-interaction protein, FIP200, to the kinase domain inactivates 
FAK [Abbi et al., 2002]. Intramolecular constrains as seen in alternatively 
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spliced isoforms of FAK which have additional residues around Tyr397 
changes the activation kinetics of FAK from trans- to cis-phosphorylation 
[Toutant et al., 2002]. FERM domain binds to the kinase domain in trans and 
inhibits FAK activity as removal of FERM domain increases FAK activation. 
FERM domain also mediates binding of interacting partners like ezrin and 
TRIO, a GEF, which increases FAK’s catalytic function [Mitra et al., 2005].  
FAK plays an important role in cytoskeletal dynamics, which involves 
direct and indirect regulation of RhoGTPases. The activated Src in the Src-
FAK complex leads to the phosphorylation of Tyr861 on FAK which mediates 
the binding of the proline-rich regions of FAK with SH3 domain-containing 
proteins, namely p130Cas. Tyr925 phosphorylation by activated Src is 
necessary for SH2-mediated binding site for Grb2, an adaptor protein, which 
leads to the activation of Ras and its downstream signalling. The following 
activation of MLCK downstream of Erk2 modulates focal adhesion dynamics, 
cell proliferation and survival signalling [Hanks et al., 2003; Mitra et al., 
2005]. It has been shown that over-expression of DLC1 leads to 
dephosphorylation of FAK at Y397 and Y925 [Kim et al., 2007].  
 
1.4.3   FAK: Regulation of RhoGTPases and their regulators 
 
RhoGTPases are critical for cytoskeletal dynamics and directional cell 
movement. Coordinated functions of Rac and Rho drive the migration process, 
which requires a tight regulation by the GAPs and the GEFs [Jaffe and Hall, 
2005]. Recent studies suggest that FAK functions so as to activate and 
inactivate RhoA in a cyclical manner. In the initial stages of cell spreading, 
there is an FAK mediated tyrosine phosphorylation and localization of 
p190RhoGAP to the focal adhesions. This interaction required the presence of 
p120RasGAP. This association led to the RhoA inactivation in early cell 
spreading and this promoted polarization of the cell [Tomar et al., 2009]. 
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Whereas during the later stages of cell spreading, FAK associated with 
p190RhoGEF (Rgnef) along with paxillin and this complex localized to the 
focal adhesions as well. This also requires the tyrosine phosphorylation on 
Rgnef. By this temporally separated binding with a GAP and a GEF, FAK can 
control the process of cell spreading. The FAK-p190RhoGEF complex in 
neuronal cells during development controls axonal branching and synapse 
formation [Lim et al., 2008]. Apart from afore mentioned GAP and GEF, FAK 
also regulates the phosphorylation and localization of PDZ-GEF and LARG. 
FAK also indirectly controls Rac activity by the regulation of RhoA activity. 
This is due to the existing antagonism between RhoA and Rac. FAK also 
mediates Rac activation via phosphorylation of adaptor proteins such as 
p130Cas and PIX [Tomar and Schlaepfer, 2009]. Furthermore, FAK interacts 
with N-WASP which has been activated by Cdc42 prior to this association and 
this might work to couple the polymerization of actin with membrane 




Fig 1.6: FAK-mediated regulation of GAPs and GEFs to control RhoA 




Lamellipodial extensions coupled with focal adhesion assembly and 
disassembly at the leading and the trailing edges controls directional 
migration. Recent studies show that FAK is a key regulator of this process as 
well [Tomar and Schlaepfer, 2009]. Contrary to previous believes that FAK is 
necessary for the formation of focal adhesions, accumulating evidence suggest 
that FAK association with FAs target them for disassembly or turnover. This 
is supported by studies in FAK-/- fibroblasts which show increased FAs at the 
periphery and decreased FA turnover at the leading and trailing edges of the 
cells. Activated FAK resides in the FAs for an increased period of time 
allowing the effectors needed for the disassembly to be recruited [Webb et al., 
2004]. By controlling the RhoA and Rac activity, FAK controls the force 




1.5 Protein Phosphatase 2A 
 
Phosphorylation is one of the major post-translational modifications 
which alter the protein function and localization and plays a major role in the 
process of cytoskeletal dynamics. The reversible event of phosphorylation is 
controlled by kinases and phosphatases. Kinases like FAK, LIMK, PAK etc 
have been extensively studied during this process. On the other hand 
involvement of phosphatases have not been delved into and the importance of 
the phosphatase family of proteins in cell migration is only recently being 
understood [Larsen et al., 2003]. Phosphorylation occurs on 3 amino acids, 
namely Serine (Ser), Threonine (Thr) and Tyrosine (Tyr) with phosphorylation 
of Ser accounting for 86.4%, Thr 11.8% and Tyr 1.8% of all phosphorylation 
[Olsen et al., 2006]. Hence Ser/Thr phosphatases are of great importance. Of 
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all the Ser/Thr phosphatases that are present, PP2A and PP1 together account 
for 90% of the Ser/Thr dephosphorylation [Eichhorn et al., 2009]. Use of 
Okadaic acid, a selective but not specific inhibitor of PP2A, was seen to 
inhibit cell migration and promote tumor growth in mice [Eichhorn et al., 
2009; Wilson et al., 1991], indicating the importance of PP2A in physiological 
and pathophysiological conditions.  
 
1.5.1 PP2A: Structure 
 
PP2A belongs to a family of holoenzyme complexes which have 
distinct localizations, different substrate specificities and activities. PP2A are 
structurally complex existing in a dimeric (PP2AD) or a trimeric form 
(PP2AT). The dimer consists of the catalytic and the scaffold subunit, known 
as the core enzyme and the trimer consists of the core enzyme with the 
additional regulatory subunit and this is known as the holoenzyme and it is 
functionally active.  
1.5.1.1 PP2A catalytic subunit (PP2AC) 
 
 The catalytic domain is globular structure that gives rise to a bimetallic 
active site for hydrolysis. It shares 50% sequence identity with PP1. PP2AC 
has two isoforms, Cα and Cβ, expressed ubiquitously by two distinct genes 
and share 97% sequence identity and are 35 kDa in size. Cα, which has 10 
times higher expression level due to a stronger promoter is mainly expressed 
in the plasma membrane compared to Cβ which is usually expressed in the 
cytoplasm and the nucleus [Eichhorn et al., 2009; Seshacharyulu et al., 2013].  
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) which binds the scaffold and regulatory 
subunits. Binding of the regulatory subunit depends entirely on methylation or 
phosphorylation of this region. Inadequacy of Cβ in substituting the function 
of Cα as observed in Cα knockout mice which are embryonic lethal suggests 
that the two isoforms of PP2AC are non-redundant in their functions despite 
being 97% identical in their sequences [Eichhorn et al., 2009; Seshacharyulu 
et al., 2013].  
 
 
Fig 1.7: PP2A subunits 
1.5.1.2 PP2A structural subunit (PR65 or PP2A-A)  
 
PP2A structural or the scaffold subunit, like the catalytic subunit, is 
encoded by two ubiquitously expressed genes, giving rise to isoforms Aα and 
Aβ. They share 87% sequence identity, with Aα accounting for a higher 
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percentage in the holoenzyme in the adult. Aβ isoform is seen in abundance in 
oocytes and in early stages of development. Despite the high percentage of 
sequence identity, similar to the PP2AC, Aβ cannot substitute for the loss of 
Aα in mice. At the C-terminal of this subunit there is 
Huntington/elongation/A-subunit/TOR (HEAT) sequence in 15 tandem 
repeats of 39 amino acids. Each repeat consists of two α-helices connected by 
intra- and inter- repeat loops. The first 10 repeats allow binding to the 
regulatory subunit and the rest mediate the binding with the catalytic subunit. 
In the dimeric form, the binding of structural subunit to the catalytic subunit 
changes its catalytic specificity.  Once the core enzyme is formed, the scaffold 
subunit bends and forms a horseshoe shape-like structure. This allows the 
structural subunit to recruit the regulatory subunit to form the holoenzyme as 
well allows the catalytic subunit to interact with the substrate unimpeded.  
The two isoforms bind to different regulatory subunits and even 
thought the Aβ is lower in abundance, many tumor-specific mutations which 
prevent it from forming the holoenzyme, have been identified in it [Eichhorn 
et al., 2009; Seshacharyulu et al., 2013].  
 
1.5.1.3 PP2A regulatory subunit 
 
This is the most diverse of the PP2A subunits with 15 genes that 
encode 26 different transcripts and splice variants. Subunit B is regulatory 
subunit and it determines the substrate specificity, controlling the activity of 
the holoenzyme in a temporal and spatial manner. Existence of multiple 
subunits gives rise to multiple functionally viable PP2A heterotrimeric 
complexes. With PP2A and PP1 controlling 90% of the Ser/Thr phosphatase 
activity, multiple PP2A holoenzymes can account for the diversity of the 
phosphoproteins and signalling pathways that get regulated by PP2A. The 
regulatory subunits do not share any sequence similarities except for the few 
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conserved amino acids which mediate the binding with the HEAT repeats in 
the scaffold subunit. This subunit has been divided into four families: B 
(B55/PR55), B’ (B56/PR61), B’’ (PR48/PR72/PR130), and B”’ 
(PR93/PR110), with the numbers indicative of the size of the protein in kDa.  
The regulatory subunits are unique in their expression patters in different 
tissues at various developmental stages [Eichhorn et al., 2009; Seshacharyulu 
et al., 2013]. It is interesting to note that the B56 subunit is responsible for 
targeting PP2A to the focal adhesions via its ability to interact with paxillin 
[Ito et al., 2000].  
 
1.5.2 PP2A: tumorigenesis 
 
PP2A’s role in cancer was identified when Okadaic acid treatment was 
observed to induce tumor in mice. Aberrant expression or mutation of the 
regulatory and scaffold subunit of PP2A has seen in various cancers. Loss-of-
function mutations in PR65 or the structural subunit was seen in lung, colon, 
breast, skin, cervical and ovarian cancers. Reduced expression of PP2A-A, 
observed in glioma as well as in vivo mice studies, led to decreased expression 
of the holoenzyme indicating a lower tumor suppressive function of PP2A. 
PP2A also, regulates GTPases like RalA which plays an important role in 
migration, cell proliferation, apoptosis, transcription and transport. Upon 
PP2A inhibition, RalA gets hyperphosphorylated [Eichhorn et al., 2009; 
Seshacharyulu et al., 2013].  
Of the various regulatory subunits of PP2A, the B55 and B56 were the 
most commonly mutated ones in cancer. B55 suppression leads to sustained 
activation of Akt which enhanced cell proliferation [Manning and Cantley, 
2007]. B56 subunit of PP2A is known to play an important role in controlling 
various signalling pathways. p53 gets directly dephosphorylated by B56-
containing holoenzyme, which stabilizes and upon B56 inhibition, p53 
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mediated signalling pathway gets deregulated [Li et al., 2007]. This subunit 
also destabilizes c-myc, an oncogene, by dephosphorylating it and targeting it 
for ubiquitination [Arnold and Sears, 2006]. A truncation mutant of B56 
increases the metastatic potential of B16 melanoma cells due to its inability to 
dephosphorylate paxillin [Ito et al., 2000]. Mitogen-activated protein kinase 
(MAPK) signalling and the WNT signalling is also directly affected by B56-
associated PP2A. This holoenzyme directly dephosphorylates ERK thereby by 
acting as a negative regulator of the MAPK signalling cascade. Similarly in 
the WNT signalling PP2A destabilizes β-catenin, leading to its degradation. 
Deregulation of MAPK and WNT signalling are seen to play a part in 
tumorigenesis, hence fortifying the role of PP2A as a tumor suppressor 
[Eichhorn et al., 2009; Seshacharyulu et al., 2013].  
 
1.5.3: PP2A: Cell adhesion and motility 
 
Activation of Akt is critical to cell migration and it is tightly regulated 
and any disruption in this leads to loss of cell polarity. Regulation of Akt by 
PP2A makes it a key player in the process [Hunter, 1995]. PP2A also inhibited 
EGFR mediated chemotaxis in keratinocytes via its dephosphorylation of ERK 
[Pullar et al., 2003]. Dephosphorylation by PP2A maintains cell adhesion and 
cytoskeleton dynamics. Epithelial cell migration is important for the process 
of wound healing which was inhibited by PP2A, which was also seen to 
inhibit endothelial cell migration therefore affecting angiogenesis [Gabel et 
al., 1999]. PP2A is seen to localize with β1-integrin and hence regulates the 
FAK complex. It was seen that upon PP2A inhibition FAK/Src/paxillin 
complex gets hyperphosphorylated, which lead to disorganization of focal 
adhesion sites and increased endothelial cell migration [Young et al., 2002]. 
PP2A is also needed to maintain the cytoskeletal integrity, upon inhibition of 
which cell exhibit a rounded morphology as well as increased motility. 
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Conversely, PP2A is also seen to stimulate migration by dephosphorylation of 
actin depolymerising factor (ADF)/cofilin, which is required to be localized to 
the lamellipodium in a dephosphorylated state for directional migration 
[Ambach et al., 2000].  
1.6 Hypothesis and Objectives 
 
 DLC1 is a focal adhesion localizing protein. It requires interaction with 
the tensin family of proteins and the residue Y442 was shown to be important 
for this function [Qian et al., 2007]. And more recently it was shown that it 
interacts with talin and FAK through an LD-like motif which is also seen to 
affect the ability of DLC1 to localize to the focal adhesions. In fact, the 
authors showed that DLC1 lacking the ability to interact with both the proteins 
was more impaired in its focal adhesion targeting than the one lacking binding 
capabilities to only one [Li et al., 2011]. It was also shown that over-
expression of DLC1 leads to the dephosphorylation of FAK at Y397 and Y925 
residues [Kim et al., 2008]. DLC1 being a tumor suppressor is deleted or 
mutated in a multitude of cancers. One such study done to identify potential 
mutational hotspots in DLC1 at the focal adhesion targeting region picked up 
two residues T301 and S308. Mutations in these residues affected DLC1s 
expression as well as the RhoGAP activity [Liao et al., 2008]. Why and how 
the mutations in these residues have such a profound effect on DLC1 is 
unknown. These residues being Ser/Thr could possibly be subject to 
posttranslational modifications such as phosphorylation which affects DLC1s 
function.  
 DLC1, due to the presence of a highly serine-rich region, is a potential 
target downstream of various kinases and phosphatases, which by controlling 
DLC1s phosphorylation status can control its regulation. A few 
phosphorylation sites on DLC1 have been delineated in the past decade which 
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have been seen affect its function as well as use of Okadaic acid, a PP2A 
inhibitor, has been shown to affect DLC1s phosphorylation status [Ko et al., 
2013; Ko et al., 2010a; Scholz et al., 2008]. B56 subunit of PP2A is known to 
localize to focal adhesions as well [Ito et al., 2000]. What is lacking is a 
complete picture on how and by what mechanisms DLC1 gets regulated to 
switch between the active and inactive states. DLC1 being a GAP for RhoA, 
has to be under tight spatial and temporal control. 
 With the knowledge that we have on the localization of DLC1, FAK 
and PP2A and the role they play in cell migration, we hypothesize that 
interplay between these molecules might be responsible for DLC1-mediated 
regulation of cell dynamics.  
 The objectives of the project to delineate the finer details of this 
regulation are to: 
1. Examine the interaction between PP2A and DLC1 
2. Delineate the residues that might be potential target for PP2A 
3. Identify a potential kinase which primes DLC1 as a PP2A target 
4. Elucidate the interplay among the three molecules of interest 


























2 MATERIALS AND METHODS  
 
2.1  Phosphoproteomic analysis 
 
Flag-DLC1 construct was transfected in 293T cells as outlined in 
section 2.4.3 and starved in serum-free media for 18 hours. Following this, the 
cells were subjected to the following treatments: DMSO; DMSO+EGF; 
U0126+EGF; Okadaic acid; Okadaic acid + EGF. After which, the cells were 
lysed using RIPA buffer supplemented with fresh cocktail of protease inhibitor 
(Roche) and immunoprecipitated using M2 anti-Flag agarose beads (section 
2.6.2) and washed thrice in ice cold RIPA buffer. The samples were then 
mixed with an SDS-buffer without β-mercaptoethanol (0.1 M Tris-HCl (pH 
6.8), 3 % (v/v) sodium dodecyl sulfate (SDS) (1st Base), 15 % glycerol 
(Merck), 0.005 % (w/v) bromophenol blue (BioRad)). To this a final 
concentration of 10mM Dithiothreitol (DTT) was added and the samples were 
boiled for 30mins at 55-60 °C. This was then let to cool down to room 
temperature and to this 20mM final concentration of freshly prepared 
Iodoacetamide (IAA) was added and was allowed to stand at room 
temperature for 30mins. DTT acts as a reducing agent while IAA acts as an 
alkylating agent.  
The sample was then ready to be loaded on to a 10% acrylamide gel 
and SDS-PAGE was performed. The gel was then fixed using a solution 
containing 10 % acetic acid and 25 % isopropanol. It was then washed a few 
times with deionized water with care being taken to prevent the gel from 
tearing and stained with PageBlue™ solution (Fermentas) overnight. The next 
day, the stain was removed and the gel was washed with deionized water 
multiple times for the purpose of destaining the gel. Once the bands become 
clearer on the gel, they were excised using a sterile scalpel and put into an 
eppendorf tube containing 100 μl of deionized water. The bands were then 
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analysed using AB SCIEX TripleTOF® 5600+ mass spectrometry system to 
analyse the phosphorylated residues on DLC1. Only phospho-residues 
containing peptides with a confidence level score above 95% was chosen. The 
residues were compared across the different treatments and only those that 
were unique to the treatment of Okadaic acid+EGF were used for further 
studies. 
  
2.2  Generating DLC1 and PP2AC constructs 
 
The full-length DLC1 constructs, the GAP-inactive DLC1 (DLC1-
R677E) and the truncation mutants of DLC1, namely, Flag-SR1, -SR2 and 
SR3 were previously generated by Wong Ming Zhi, Denise, Dr. Zhou Yi Ting 
and Dr Zhong Dandan. Using Polymerase Chain Reaction (PCR), gel 
extraction, restriction digestion, ligation, transformation and plasmid 
extraction, the internal deletion mutant of DLC1 (DLC1-S), point mutants of 
DLC1 (T301/S308A and T301/S308D) point mutant of PP2AC were generated 
The protocols of  the afore mentioned experiments are discussed in detail in 
this section.  
The previously generated DLC1 constructs were all cloned into the 
pXJ40 vector (Flag and GFP-tagged), kindly provided by Dr. E. Manser 
(Institute of Molecular and Cell Biology, Singapore). This vector is a 
mammalian expression vector containing the CMV promoter with the tag 
attached to its 5’end. The template used for construction of PP2A mutants was 





2.2.1 Polymerase Chain Reaction (PCR) 
 
 The existing plasmid constructs were used for the purpose of carrying 
out PCR to create point mutations and internal deletions in the case of DLC1, 
sub-coning of FAK and point mutations in the case of PP2A. Templates used 
for DLC1 point mutants and internal deletions were pXJ40-Flag-DLC1 and 
pXJ40-GFP-DLC1, for FAK sub-cloning was mouse FAK cloned into 
pCDNA and for PP2AC-CS mutant was pXJ40-myc-PP2AC. The primers used 
for the purpose are given in table (2.1).  
For the PCR, the set up was as follows: For a 50μl reaction- 2.5 U of 
Pfu Turbo DNA Polymerase, corresponding 1 X Pfu Turbo DNA Polymerase 
reaction buffer (Stratagene, USA), 10pmol of the specific forward and reverse 
primer oligonucleotides each, 0.2mM dNTP mix, 100ng of the template and 
the reaction mix was topped upto 50μl with deionized autoclaved water. Pfu 
Turbo was used because the templates to be amplified were greater that 1 kb in 
length.  
The PCR reaction was carried out in a thermal cycler (BioRAD 
icycler). The parameters of the PCR cycles were set as follows: Initial 
denaturation step at 95 °C for 2mins followed by 20 cycles consisting on the 
following steps: Denaturation at 95 °C for 2 mins; Annealing at 55-65 °C for 
30secs (Temperature determine by the Tm of the primer pair); Extension at 72 
°C for 1min/kb of DNA template. This was followed by a final extension step 
at 72 °C for 12-15mins. For the point mutation PCR products, 10 μl of the 
reaction mix was subjected to DpnI digestion at 37°C for 30-45mins post-
PCR. 
For the purpose of creating the internal deletion mutant of DLC1, 
nested PCR was done. For this 2 pairs of primers (S_F1 and S_R1; S_F2 
and S_R2) were designed, with the forward of the first pair (S_F1) 
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containing the BamHI restriction site and the reverse primer of the second pair 
(S_R2) carrying the XmaI restriction site. The reverse primer of the first pair 
(S_R1) and forward primer of the second pair (S_F2) were designed for the 
region surrounding but excluding the amino acids to be deleted. For the first 
round of PCR, two set ups were made with each primer pair. For the second 
round of PCR, the products from the previous rounds were used with the 
S_F1 and S_R2 as the primer pair. These were then subjected to restriction 
digestion at 37°C for 4hours.  
 
 





Primer Name Primer sequence 
T301/S308A 
AA_F 5’ – CAGCAGCAGCAGCGCACAGTCGGAG 
ACCAGC – 3’ 
AA_R 5’ – GCTGGTCTCCGACTGTGCGCTGCTGC 
TGCTG – 3’ 
T301/S308D 
DD_F 5’ –CAGCAGCAGCAGCGACCAGTCGGAG 
ACCAGC – 3’ 
DD_R 5’ – GCTGGTCTCCGACTGGTCGCTGCTG 
CTGCTG - 3’ 
DLC1_S 
S_F1 5'- CGCGATATCGACAAAGAAGATGATAT 
TACTGAGCT -3' 
S_R1 5' –CGCTGCTGGTCTCCGACTGGGTCTGCGT 






S_R2 5'- CGCGATATCGTGGTTATTTGATGGGATC 
CAAGAGA -3' 
PP2AC-CS 
CS_F 5’ – GCTCCAAACTATAGTTATCGTAGTGGT 
AACCAAG – 3’ 
CS_R 5’ – CTTGGTTACCACTACGATAACTATAGTT 




FAK_F 5’ – ATGCGGATCCATGGCAGCTGCTTATCTT 
– 3’ 
FAK_R 5’– ATGCGGTACCTCAGTGTGGCCGTGTCTG 
– 3’ 
 
2.2.2 Agarose gel electrophoresis 
 
 Only in the case of DLC1 internal deletions, once the PCR products 
were obtained (after restriction digestion the products were subjected to the 
same), agarose gel electrophoresis was carried out to separate the DNA 
fragments of the required size from the rest. 1% (w/v) agarose gel was made 
by dissolving the required weight of Agarose (1
st
 Base) in 1 X TAE buffer (40 
mM Tris base, pH 8.0 with glacial acetic acid, 10 mM EDTA). For 
visualization of DNA under ultraviolet light, SYBR®Safe DNA gel stain 
(Invitrogen) at a dilution of 1:50,000 was mixed with the gel prior to setting. 
This gel was run using 1 X TAE as the buffer. Alongside the products, 1 kb 




2.2.3 Gel extraction 
 
 Following the agarose gel electrophoresis, the separated DNA bands 
were visualized under UV light in the Molecular Imager Gel Doc XR system 
(BioRad) and the required bands were excised out using a sterile scalpel. 
These bands were then extracted from the gel using the QIAquick Gel 
Extraction Kit (QIAGEN) using the instruction manual provided by the 
manufacturer. The bands were eluted out using deionized autoclaved water 
and were used for further processing as required. 
 
2.2.4 Restriction enzyme digestion 
 
 PCR products after gel extraction along with the vectors/constructs 
were digested with corresponding enzymes as designed into the primers. 1.5 
μg of each of the DLC1 plasmid construct and the PCR product was digested 
using BamHI (New England Biolabs) and XmaI (New England Biolabs) in a 
total volume of 50 μl consisting of 1X reaction buffer 4 (as determined by the 
manufacturer), 1X bovine serum albumin (BSA), 4 U of the enzyme for every 
μg of DNA to be digested in the case of vector digestion and for the PCR 
products a total of 25 U was used. This set up was kept for 4 hours at 37 °C. 
The digested products were subjected to agarose gel electrophoresis and gel 
extraction as described previously.  
  
 For the purpose of FAK sub-cloning, BamHI and KpnI (New England 
Biolabs) were used to digest the PCR product as well as pXJ40-Flag and 
pXJ40-GFP vectors. The protocol used was similar to that used for DLC1.  
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2.2.5 Ligation  
 
 For internal deletion, fragment of DLC1 lacking the 5 amino acids 
(15bps) was inserted back into pXJ40-Flag/GFP DLC1 constructs after 
digestion of both the constructs and the PCR product. Ligation carried out 
overnight at 16 °C. The PCR product to the digested construct concentration 
was about 2:1, for a total volume of 20 μl , with 1X ligase buffer (New 
England Biolabs) and 1μl of 200 U T4 DNA ligase (New England Biolabs). 
 The digested vector and PCR product were ligated using the same 
protocol for FAK sub-cloning. 
 
2.2.6 Preparation of competent cells 
 
E. coli DH5α was used as the preferred choice for cloning because of a 
mutation in its endA gene that reduces its synthesis of endonuclease enzyme, it 
allows for production of plasmid DNA of high purity as well as yields a high 
concentration of DNA. 
These bacterial cells were made competent using the 
calcium/manganese based (CCMB: 80 mM CaCl2.2H2O, 20 mM 
MnCl2.4H2O, 10 mM MgCl2.6H2O, 10 mM KOAc pH 7, 10 % (v/v) Glycerol; 
pH 6.4, filtered) method. The preferred growth media and agar for E. coli 
DH5α cells are Luria Bertani (LB) broth and agar (BD Difco). The bacterial 
cells were first streaked onto an LB Agar plate without antibiotics from 
glycerol stock and incubated overnight at 37 °C. Inoculating a colony from 
this plate the next day into 5ml of LB broth, a starter culture was prepared and 
incubated overnight at 37 °C in a bacterial shaker incubator at 250 rpm. The 
next day, 50 ml of LB broth was inoculated with the starter culture and the 
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culture was grown at 37 °C with shaking till an OD measured at 600 nm 
reached 0.6. The culture was then chilled on ice for 10 minutes before it was 
pelleted at 2,500 rpm for 10-15 minutes at 4 °C. The pellet obtained in this 
step was resuspended by gentle vortexing with 1/3
rd
 the original volume of the 
culture (17ml) of ice cold CCMB. This was then incubated on ice for 20 mins. 
This is pelleted again by centrifuging at 3,000 rpm for 10 minutes at 4 °C, 
following with the pellet was resuspended again in ice cold CCMB which is 
1/12
th
 the original volume of culture (4ml). The cells are then aliquoted (100μl 
each), snap frozen in liquid nitrogen and stored at -80 °C for future use. 
 
2.2.7 Transformation of ligated products into competent bacterial 
cells  
 
 Transformation of the DNA into competent cells can be done using 
two different protocols. For the purpose of transforming ligated products the 
heat-shock method is used which has high efficiency of transformation. The 
other method is the KCM method, which is mainly used for the purpose of 
retransformation of plasmid DNA.  
In the heat-shock method, the E. coli DH5α of competent cells were 
first thawed out on ice. To this about 10 μl of the ligation product was added, 
mixed and incubated on ice for 30 mins and then was subjected to heat shock 
by keeping it at 42 °C for 90 seconds followed by 5 mins incubation on ice 
again. To this mixture, 600 μl of LB broth (without antibiotics) was then 
added and the sample was incubated in 37 °C at 250 rpm for 1 hour for 
recovery. The sample was then concentrated by pelleting and plated onto LB 
agar plates with ampicillin (100μg/ml) and incubated overnight at 37 °C. 
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 In the KCM method, to about 20 μl of KCM (100 mM KCl, 30 mM 
CaCl2, 50 mM MgCl2) 1μl of the plasmid DNA was added and incubated on 
ice for 5mins. Simultaneously E. coli DH5α cells were thawed out on ice. 20 
μl of the competent cells were added to the nixture and incubated on ice for 
20-30mins and plated onto LB agar plates with ampicillin (100μg/ml). The 
plates were incubated overnight at 37°C.  
 
2.2.8 Plasmid DNA extraction 
 
 Colonies were picked from the LB agar plates, inoculated in 5ml LB 
broth with ampicillin (100μl/ml) and incubated overnight at 37°C at 250rpm. 
These cultures were pelleted down and plasmid DNA was extracted using the 
AxyGen minprep kit, following the manufacturer’s instruction. The plasmid 
DNA was eluted using deionized autoclaved water and its concentration 
checked using the NanoDrop 2000. OD260:OD280 ratio was checked to ensure 
the purity of plasmid DNA obtained (ratio of 1.8-2 is indicative of highly pure 
DNA devoid of protein contaminants). This plasmid DNA can be used for the 
purpose of DNA sequencing and checking for plasmid expression.  
For the purpose of higher concentration and purity 50ml of inoculated 
culture can be used for plasmid DNA extraction using AxyGen Midiprep kit as 
per the manufacturer’s instructions.  
 
2.2.9 Sequencing of DNA constructs 
 
 The purified plasmid was processed for the purpose of sequencing so as to 
ensure that the insertion was within frame and there were no mutations in the 
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case of the DLC1 internal deletion and that the correct substitutions were 
made for the point mutants generated for DLC1 and PP2AC. For this purpose 
T7 forward primer as well as DLC1 and PP2AC internal primers were used.  
The reaction mix for this PCR contained 100ng of plasmid DNA, 0.8μl of the 
relevant primer, 1Xsequencing buffer, 1μl of BigDye. The PCR set up was as 
follows: : Denaturation for 30 seconds at 96°C; Annealing for 15 seconds at 
55°C and Extension for 4 minutes at 60°C. This was repeated for 25 cycles.  
The PCR product obtained is ethanol precipitated to purify. The 
reaction mix for this procedure contains 62.5μl of 95% Ethanol, 3μl of 3M 
sodium acetate, with 5μl of PCR product. The total volume was maed upto 
80μl and incubated at room temperature for 15-20mins. The DNA was 
pelleted by centrifuging the reaction mix at maximum speed (14,000 rpm) for 
10 mins. The supernatant was decanted and 500μl of 75% ethanol was added 
and this was centrifuged at 14,000 rpm for 5mins. Ethanol was removed and 
the remaining ethanol in the tube was air-dried or dried at 85°C. The samples 
were then processed by HiDi and sequenced in the the ABI PRISM 3130 
Genetic Analyzer (Applied Biosystems) by the Department of Biological 
Sciences. The obtained sequences were analysed using the BLAST ((Basic 
Local Alignment Search Tool) program on the NCBI (National Center for 
Biotechnological Information) website 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).  
 
2.2.10 Checking expression of cloned constructs 
 
 The different mutants of DLC1 and PP2AC were first checked for 
expression. This was done by transfecting the plasmid DNA into 293T cells, 
followed by lysis of the cells by RIPA buffer. The lysate was then separated 
by SDS-PAGE and analysed by Western blotting using antibodies specific to 
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the tag attached to the protein or the protein itself. The protocols for these are 
outlined in the coming sections.  
2.3      Expression and purification of GST-fusion proteins in 
bacteria 
  
 pGEX-4T-1 vector containing GST-tagged RBD was transformed into 
E.coli. DH5α cells. Inoculating a colony from this plate the next day into 5ml 
of LB broth, a starter culture was prepared and incubated overnight at 37 °C in 
a bacterial shaker incubator at 250 rpm. The next day, 50 ml of LB broth was 
inoculated with the starter culture and the culture was grown at 37 °C with 
shaking till an OD measured at 600 nm reached 0.6. Once the culture reaches 
the correct OD, 0.1 mM IPTG was added in to induce the expression of GST-
tagged proteins with over-night shaking at 25 °C. The next day, the cell pellets 
were collected by centrifugation at, followed by freezing in -80 °C for 1 hour. 
The pellets were then thawed on ice, resuspended in chilled RBD lysis buffer 
(1XPBS, 1% Triton-X-100). To this 100mM DTT (w/v) and a mixture of 
protease inhibitors (Roche Applied Science) were freshly added. The 
resuspended pellet was lysed by sonication using MISONIX Sonicator XL 
2020, set to a program of 3.0 sec pulses with a 6.0 sec lag period for a period 
of 3 mins at an amplitude of 20%. The cell lysate were centrifuged at 5000 
rpm for 20 mins at 4°C. The supernatant was incubated with required amount 
of Glutathione Sepharose 4B beads (Amersham Sciences) at 4°C over night. 
Beads with GST-tagged proteins were washed 3 times with chilled RBD lysis 
buffer followed by 2-times washing with chilled 1XPBS and finally the beads 
were resuspended in equal volume of 1XPBS. 
 To check for the expression, 10 μl of the beads were boiled with the 
loading buffer and together with BSA standards were run on acrylamide gel. 
62 
 
The gel was stained with Coomassie Brilliant Blue stain for 1 hour and 
destained using water till the bands were clearly visible.   
 
2.4 Mammalian cell culture and Transfection 
 
 For the purpose of the experiments in this thesis, the mammalian cells 
lines used were 293T and HeLa JW. 
2.4.1 293T 
 
293Ts are human embryonic kidney epithelial cells (American Type 
Cell Culture) with stable expression of SV40 T antigen. These cells were 
cultured as a monolayer on tissue culture dishes (Nunc) in Roswell Park 
Memorial Institute (RPMI) 1640 medium containing glutamine (10.4 g of 
HyQ RPMI - 1640 powder in 1 L of deionized autoclaved water) 
supplemented with 2 g/L sodium bicarbonate, 10 mM HEPES free acid, 100 
U/ml penicillin-streptomucin (all from Hyclone Laboratories) and 10 % (v/v) 
defined fetal bovine serum (FBS) (LifeTech) and maintained in an incubator at 
37 °C with 5 % carbon dioxide.  
  
2.4.2    HeLa JW 
 
These cells were a kind gift ftom Dr Alexander Bershadsky’s Lab. 
These cells are a modification of HeLa cells, which are immortalized cervical 
cancer cell line. They were grown in Dulbecco’s Modified Eagle’s Medium 
containing glutamine (13.2g of HyQ DMEM-High Glucose powder in 1 L of 
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deionized autoclaved water) supplemented with 5g/L sodium bicarbonate, 100 
U/ml penicillin-streptomycin solution (Hyclone Laboratories) and 10% (v/v) 
FBS (LifeTech) as a monolayer in tissue culture dishes (Nunc) and maintained 
in an incubator at 37 °C with 5 % carbon dioxide. 
2.4.3 Transfection of 293T cells 
 
24 hours prior to transfection the cells were subjected 0.25 % trypsin-
EDTA (LifeTech) treatment and plated in 10% RPMI-1640 onto required size 
of tissue culture dishes so as to achieve 80% confluency for the purpose of 
transfection. Before seeding the cells, the culture dishes were coated with 
poly-D-lysine for 15mins at 37°C and then washed thrice with PBS. For 
transfection, Mirus TransIT®- Transfection reagent (Mirus Bio Corporation) 
was used (For every μg of plasmid DNA 3μl of transfection reagent was used). 
The required volume of transfection reagent was incubated in 250-500 μl of 
serum-free RPMI - 1640 for 5 mins at room temperature prior to addition of 
plasmid DNA, followed by 20 min incubation at room temperature. This mix 
was added drop-wise to the culture plates, which were swirled to ensure even 
distribution of the complex. These plates were incubated at 37 °C for 24 hours 
with 5 % carbon dioxide. Before transfection, the media in the tissue culture 
dishes were replaced with fresh 10% RPMI-1640. 4 hours post-transfection, 
this medium was replaced with 0% RPMI-1640, subjecting the cells to 18 
hours of starvation for experimental purposes. 
 
2.4.4 Transfection of HeLa JW cells 
 
24 hours prior to transfection the cells were subjected 0.25 % trypsin-
EDTA (LifeTech) treatment and plated in 10% DMEM onto required size of 
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tissue culture dishes so as to achieve 80% confluency for the purpose of 
transfection. For transfection Lipofectamine™ 2000 transfection reagent (Life 
Technologies) was used (For every 2μg of plasmid DNA 4.5 μl of transfection 
reagent was used.). The required volume of transfection reagent was incubated 
in OPTI-MEM® reduced serum medium (Gibco) for 5 minutes at room 
temperature (For every 2μg of plasmid DNA 150 μl of OPTI-MEM® was 
used.). The plasmid DNA was similarly diluted in OPTI-MEM® reduced 
serum medium and this was then added to the transfection reagent complex 
and incubated for 20 mins at room temperature. This mix was added drop-wise 
to the culture plates, which were swirled to ensure even distribution of the 
complex. These plates were incubated at 37 °C for 24 hours with 5 % carbon 
dioxide. Before transfection, the media in the tissue culture dishes were 
replaced with fresh 10% DMEM. 4 hours post-transfection, this medium was 
replaced with 0% DMEM, subjecting the cells to 18 hours of starvation for 
experimental purposes. 
 
2.5 EGF stimulation, U0126/Okadaic Acid/FAK inhibitor 
Treatment: 
 
For doing a time-dependent study on the effect of EGF stimulation on 
the binding of DLC1 and PP2AC as well as other effects, 4 hours post-
transfection, the cells were kept in a serum-free media for 18-24 hours. These 
cells were then treated with EGF (Sigma) at a concentration of 100ng/ml. The 
cells were then lysed at set time intervals using RIPA lysis buffer and analysed 
using SDS-PAGE and western blotting. 
To confirm if the effect seen in the experiments were indeed 
downstream of MEK/ERK1/2, the cells were subjected to MEK/ERK inhibitor 
U0126 treatment. The concentration of U0126 (Promega) used is 5μM. It was 
added 1 hour prior to stimulation with EGF. U0126 is stably dissolved in 
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DMSO hence the control cells were treated with DMSO of the same volume 
as U0126, to negate the effect of DMSO from the experiment.  
FAK inhibitor used was PF-573228 (Sigma) at a concentration of 
300ng/ml. The treatment protocol followed is same as that of U0126, with the 
treatment starting 1 hour prior to EGF stimulation/lysis. In the case of Okadaic 
Acid (Enzo Life Sciences), it was used as at a concentration of 100nM and the 
cells were treated 2 hours prior to EGF stimulation/lysis. In both the cases the 
control cells were treated with DMSO as both the compounds were dissolved 
in DMSO. Following the treatments, the cells were lysed in RIPA buffer and 




2.6.1 Preparation of mammalian whole cell lysates 
 
 The mamamlian cells were lysed after the respective treatments using 
RIPA buffer (150 mM sodium chloride, 50 mM Tris, pH 7.3, 0.25 mM EDTA, 
1% (w/v) sodium deoxycholate, 1% (v/v) Trition X-100, 50 mM sodium 
fluoride).  To this a mixture of protease inhibitors (Roche Applied Science) 
was freshly added before every experiment. The cells were centrifuged at 
maximum speed (14,000 rpm) for 10 mins and the supernatant collected for 







For co-immunoprecipitation, cells were transfected with the required 
constructs, proteins of which were being tested for binding. For this, atleast 
one of the transfected constructs was Flag-tagged. After lysing the cells, some 
amount of the whole cell lysate was set aside for checking for various proteins. 
The rest of the whole cell lysate as incubated with 7-10 μl of M2 anti-Flag 
agarose beads (Sigma-Aldrich) at 4 °C for 4 hours. The agarose beads were 
then washed with RIPA buffer thrice and the bound complex analysed by 
SDS-PAGE and western blotting. 
 
2.7 RBD assay 
 
The endogenous RhoA activity was examined with pull-down assays 
with GST-tagged RBD domain of rhotekin which can specifically bind to 
GTP-bound RhoA (Ren et al., 1999; Wheeler and Ridley, 2004; Shang et al., 
2003). The transfected cells were subjected to respective treatments and lysed 
with RIPA buffer. To 20 μl of lysates, 180 μl of RIPA buffer was added and 
incubated with 20 μl of GST-tagged RBD bound to glutathione sepharose 
beads for 45mins at 4 °C. This complex was then washed thrice with RIPA 
buffer. This was processed using SDS-PAGE.  Immunoblotting was done for 
rulled-down active RhoA, endogenous RhoA and the over-expressed proteins 





2.8     SDS-PAGE gel eletrophoresis and western blot analysis 
 
The proteins were analyzed on 4-12.5% SDS-polyacrylamide gels 
(SDS-PAGE) with a Mini Protean II electrophoresis apparatus (BioRad 
Laboratories). The gels were cast with glass plates containing 1.5 mm spacers 
and 15-well combs (BioRad Laboratories). 12.5% gels were used for resolving 
smaller molecular weight proteins around 20-25 kDa, 4% gels were used for 
the purpose of resolving phosphorylated DLC1 and 10% gels were used for 
the rest of the experiments. The resolving or the separating gel contained 4-
12.5% (w/v) acrylamide, 0.48% (w/v) N-N’-methylbisacrylamide, 0.375 mM 
Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.0075% (w/v) APS and 0.05% (v/v) 
TEMED (N, N, N', N'-tetramethylethylenediamine). The stacking gels 
contained 4% (w/v) acrylamide, 0.133% (w/v) N-N’-methylbisacrylamide, 
0.125 mM Tris-HCl pH 6.8, 0.1% (w/v) SDS, 0.0075% (w/v) APS and 0.08% 
(v/v) TEMED. To the protein samples of 6X loading dye (3% (w/v) SDS, 15% 
(v/v) glycerol, 7.5% (v/v) b-mercaptoethanol, 0.1 M Tris-HCl pH 6.8, 0.005% 
(w/v) bromophenol blue) was added and boiled at 85 °C for 3mins. The 
samples together with protein markers (Bio-Rad Laboratories) were loaded 
into the gels. Electrophoresis was performed at 25mA/gel for 1.5-4 hours 
(depending on the gel percentage) at room temperature in SDS-running buffer 
(25 mM Tris, 192 mM glycine and 0.75% (w/v) SDS).  
After eletrophoresis, proteins separated on the gels were transferred 
onto PVDF membrane (Millipore) in transfer buffer (33.7 mM Tris, 256 mM 
glycine, 20% (v/v) methanol and 0.01% (w/v) SDS) at 100 Volt for 45mins-
1hour 10min at 4oC with a Mini Trans-Blot Electrophoretic Transfer Cell 
(Bio-Rad Laboratories). 
 The PVDF membrane onto which the proteins were transferred, they 
were incubated in 1% blocking buffer (1 X PBS, 0.1 % Tween-20, 1 % BSA) 
for 1 hour at room temperature, after which the blots were incubated with 
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primary antibody diluted in 1% blocking buffer for 2 hours at room 
temperature or overnight at 4 °C. The blots were washed 3 times for a duration 
of 7-10 minutes each with wash buffer (1 X PBS, 0.1 % Tween-20). This was 
followed by incubation with secondary antibody diluted in wash buffer or 
blocking buffer for 2 hours with a repeat of the washes. To detect the proteins, 
the membranes were then treated for chemiluminescence detection using the 
ECL kit (Pierce). 
 The antibodies used were polyclonal anti-Flag (Sigma) [1:10000], 
polyclonal anti-c-myc (Zymed) [1:2500], monoclonal anti-dualphospho-
threonine-tyrosine (anti-phospho ERK1/2) (Sigma) [1:1000], monoclonal anti-
ERK2 (anti-pan ERK) (Transduction Laboratories) [1:1000], anti-DLC1 (BD 
Biosciences) [1:1000],  monoclonal pan FAK(AbCam) [1:1000], anti-FAK 
pY397( BD Biosciences) [1:1000], anti-FAK pS910 (AbCam) [1:1000] and 
PP2A-C(α/β) (Santa Cruz) [1:1000].  
 
2.9   Cell Spreading 
 
For cell spreading studies, HeLa JW cells were transfected with 
pXJ40-GFP-DLC1, pXJ40-GFP-DLC1-R677E and pXJ40-GFP and starved as 
described in section 2.4.4. Serum contains fibronectin and other matrix protein 
which assist in cell attachment to the surface of the plates. So as to maintain 
similar conditions as those used for binding studies as well as RBD assay, 6-
well plates (Nunc) was functionalized using 10% DMEM media and kept 
overnight in the 37°C incubator. After, 18-24 hours of starvation, the cells 
were subjected FAK inhibitor treatment or DMSO treatment for 1 hour. 
Following which, the cells were trypsinized, centrifuged in a falcon tube to 
remove the trypin. The cells were then re-suspended in serum free-media with 
or without FAK inhibitor, depending on the prior treatment and left for 
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recovery at 37°C with 5% CO2 for 45 mins in the incubator. 35mins into the 
recovery, to some of the falcon tubes EGF was added and left for another 
10mins. After recovery, the cells were aliquoted into the pre-functionalized 6-
well dishes. These were then left at 37°C with 5% CO2 in the incubator and 
fixed at various time points (30mins, 45mins, 60mins and 90mins). For the 
purpose of fixing, 4% Paraformaldehyde (PFA) was used. At each time point, 
the 6-well dishes were removed and washed thrice with 1XPBS. To then 
plates following the wash 1ml of PFA was added and the plates were 
incubated at 37°C for 15mins. The wash step with 1XPBS was repeated to 
remove residual PFA. 1ml of 1XPBS was added to each well to prevent drying 
up of the cells and the dishes were stored at 4°C till time of imaging. The cells 
were imaged in Perking Elmer Spinning Disk with a Olympus IX Inverted 
Microscope and a UPlansSApo 10X objective using the 488 DPSS laser and 
the bright-field.  
 
2.10     Wound Healing 
 
For the wound healing experiment, PDMS strips were used to create a 
gap or a wound in the cultured cells. This was chosen over the traditional 
scratching of a wound so as to avoid injuring the cells, which might affect the 
final outcome of the experiment. PDMS substrates were prepared using a 
Sylgard 184 silicone elastomer kit (Dow Corning). The silicone elastomer 
component was mixed with the curing agent in a ration of 10:1 and degassed 
for 30mins after which it was poured into a 35mm plate to a required depth. 
Subsequently, crosslinking of the elastomer was carried out at 70 °C for 2 
hours [Prager-Khoutorsky et al., 2011]. This gives the PDMS block just the 
right amount of stiffness to be easily cut. The PDMS block was allowed to 
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cool down to room temperature. Following this, using a clean scalpel, the 
PDMS block was cut into thin strips of the required thickness. 
Before using the PDMS strips for the experiment, they were 
thoroughly washed in 100% ethanol and rinsed with deionized autoclaved 
water. These along with the tweezers were disinfected using UV light. The 
strips were then carefully placed into the wells of a 12-well dish (Nunc) and 
pressed down to ensure they stick to the surface of the dish. The HeLa JW 
cells were trypsinized and seeded at high confluency into the wells, making 
sure not to dislodge the PDMS strips.  
24 hours later, the HeLa JW were transfected with pXJ40-GFP-DLC1, 
pXJ40-GFP-DLC1-R677E and pXJ40-GFP as described in section 2.4.4 and 4 
hours later starved in serum-free media. 18-24 hours later, the cells were 
subjected to FAK inhibitor treatment and EGF stimulation as per requirement. 
The PDMS strips were carefully pulled out without disturbing the cells. This 
forms a gap/wound in the monolayer of cells, which was then imaged to study 
the ability of the cells to migrate and close the gap/wound. The imaging was 
done using Olympus Live EZ with a Olympus IX Inverted Microscope and a 
UPLFLN 10X objective at 37°C, with 5% CO2. Warm White LED was used 
for bright field imaging and XCite Series 120Q Fluorescence light source was 
used for fluorescence imaging with a FITC (U-MNIB) filter over a period of 

























3.1 RhoGAP function of DLC1 can be modulated by EGF 
stimulation 
 
The RhoGAP function of DLC1 is known to contribute towards its 
ability to regulate various cellular processes. Its regulation of key cellular 
processes also implicates it in tumor suppression. It has been shown that the 
GAP domain of DLC1 alone is not sufficient for its role as a tumor suppressor 
and that the regions surrounding the GAP domain are vital for its activity 
[Kim et al., 2008]. Furthermore, there are multiple factors contributing to this 
function and we have shown that the pathway downstream of the EGF 
receptor is one such factor. EGF stimulation activates EGF receptor (EGFR), 
which in turn is responsible for a multitude of downstream signalling cascades 
which include the Ras-MAPK pathway, JAK/STAT pathway and PI3K/Akt 
pathway. It is thus important to elucidate the signalling cascade important for 
further downstream functions. 
 We showed that DLC1 requires stimulation by EGF to exert its GAP 
function on the endogenous RhoA (Fig 3.1). This possible effect of EGF could 
be either a direct one via phosphorylation of DLC1 or an indirect effect 
involving other potential regulators of DLC1. We explored the possibility that 
this effect was due to direct phosphorylation of DLC1 by using a lower 
percentage of acrylamide gel, to better resolve higher molecular weight 
proteins. DLC1 showed a lower electrophoretic mobility shift as seen in the 
lane 2 of the top panel of Fig 3.2. This recovers upon treating the cells with the 
Mek/Erk inhibitor U0126 (lane 3 of the top panel of Fig 3.2), indicating that 
Ras-MAPK pathway is involved in phosphorylation of DLC1. It has been 
previously shown that DLC1 gets regulated by the event of phosphorylation as 
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seen in the case of Akt phosphorylation at S567 which leads to the inactivation 
of DLC1 RhoGAP activity [Ko et al., 2010a]. However this is the first time 





Figure 3.1: EGF stimulation triggers DLC1 GAP activity towards RhoA. 
Hela JW cells were transfected with Flag-tagged DLC1 full length (FL), Flag-
R677E (GAP negative mutant), and Flag-vector. The cells were starved for 
18-24 hours in serum-free media and then stimulated for 10mins with EGF 
(100ng/ml). The cells were lysed and the whole cell lysates (WCL) were used 
for pull-down assay (PD) with glutathione-sepharose beads bound to GST-
tagged RBD. Proteins in the WCL and the PD were processed by SDS-PAGE 
and immunoblotting and probed with the appropriate antibodies. Upon EGF 
stimulation, DLC1 FL shows reduced amounts of active RhoA (top panel, lane 
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6) whereas the GAP mutant shows no difference in active RhoA levels with or 




                                         
 
 
Figure 3.2: DLC1 shows an electrophoretic mobility shift upon EGF 
stimulation. 293T cells transfected with Flag-tagged DLC1 were starved for 
18-24 hours in serum-free media and then stimulated for 10mins with EGF 
(100ng/ml). The cells were lysed and the whole cell lysates (WCL) were used 
for immunoprecipitation (IP) with M2 anti-Flag agarose beads. Proteins in the 
IP were separated using 4% gel and immunoblotted with anti-Flag, anti-
phosphoERK and anti-panERK antibodies. Upon EGF stimulation, there is an 
apparent increase in the DLC1 molecular weight (top panel, lane 2), which is 
lost upon treatment with U0126 (top panel, lane 3) indicative of possible 






3.2 Identifying PP2A as a potential interacting partner of DLC1 
 
Studies have also shown that, upon inhibition by Okadaic acid, the 
phosphorylation status of DLC1 increases, indicating that PP2A might be 
playing a significant role in regulation of DLC1. This increase in 
phosphorylation increased the association of DLC1 with a scaffold protein 14-
3-3 and blocks its GAP activity [Scholz et al., 2008]. Okadaic acid was shown 
to specifically inhibit PP2A and to a much lesser extent PP4 and PP5 [Favre et 
al., 1997]. It also targets PP1, but at a concentration 100 times more than that 
required for PP2A. It has been shown that upon Okadaic acid treatment, the 
cells become more motile [Wilson et al., 1991] and the process of cell 
migration encompasses multiple steps. With the event of phosphorylation 
playing a key role, phosphatases have a part throughout this process. PP2A via 
its interaction with paxillin through its B56 (B’) subunit [Ito et al., 2000] 
localized to focal adhesions, which have seen to be an important site for 
DLC1s GAP function.  
 
3.2.1 Confirmation of OA mediated regulation of DLC1 
phosphorylation downstream of EGF stimulation and identification 
of potential target sites 
 
With the knowledge that OA treatment causes an electrophoretic 
mobility shift in DLC1, we wanted to see whether this effect is downstream of 
EGF stimulation or independent of it. We used 100nM of OA, a concentration 
at which it specifically inhibits PP2A and observed that this electrophoretic 
mobility shift is maintained only upon EGF stimulation as seen in lane 4 of 
Fig 3.3 compared to lane 2 where there was no EGF treatment. This indicates 






Figure 3.3: Okadaic acid treatment maintains the observed DLC1 
electrophoretic mobility shift downstream of EGF stimulation. 293T cells 
transfected with Flag-tagged DLC1 were starved for 18-24 hours in serum-free 
media. The cells were treated with Okadaic acid (OA) (100nM) for 2hours and 
then stimulated for 10mins with EGF (100ng/ml). The cells were lysed and the 
whole cell lysates (WCL) were used for immunoprecipitation (IP) with M2 
anti-Flag agarose beads. Proteins in the IP were separated using 4% gel and 
immunoblotted with anti-Flag, anti-phosphoERK and anti-panERK antibodies. 
Upon treatment with EGF and OA, the observed DLC1 electrophoretic 
mobility shift is maintained. 
 
To delineate which residues on DLC1 might be potential targets 
downstream of EGF stimulation and OA treatment, phosphoproteomic 
analysis was carried out on DLC1 with various treatments. After comparing 
the phosphorylation sites between the different treatments, various sites were 
identified in the serine-rich region of DLC1 (Table 3.1).  
 
 
Table 3.1: Identification of potential phosphorylation sites on DLC1 by 
phosphoproteomics. 293T cells transfected with Flag-tagged DLC1 were 
starved for 18-24 hours in serum-free media. The cells were then treated with 
Okadaic acid (100nM) for 2hours and then stimulated for 10mins with EGF 
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(100ng/ml). The cells were lysed and the whole cell lysates (WCL) were used 
for immunoprecipitation with M2 anti-Flag agarose beads. The samples were 
boiled, and then subjected to reduction and alkylation. Proteins were then 
separated using SDS-PAGE and the gel was stained with PageBlue™ solution 
and de-stained using water. The bands were excised and used for mass 
spectrometry analysis and the sites S305-307 were identified as potential 
phosphorylation sites on DLC1. 
 
As a confirmation we also used various truncation mutants of the 
serine rich region of DLC1, namely, SR1 (77-330), SR2 (331-485) and SR3 
(486-652). Figure 3.4 shows that only SR1 showed mobility shift in SDS-
PAGE whereas SR2 and SR3 did not. The sites identified with 
phosphoproteomics lie within the SR1 region, thus providing further proof of 
















Figure 3.4: Electrophoretic mobility shift in DLC1 truncation mutant 
upon Okadaic acid treatment and EGF stimulation. A) Schematic 
representation of DLC1 serine-rich truncation mutants.  B) 293T cells were 
transfected with Flag-tagged DLC1 truncation mutants. The cells were starved 
for 18-24 hours in serum-free media. The cells were treated with Okadaic acid 
for 2hours and then stimulated for 10mins with EGF (100ng/ml). The cells 
were lysed and the whole cell lysates (WCL) were used for 
immunoprecipitation (IP) with M2 anti-Flag agarose beads. Proteins in the IP 
were separated using 12.5% gel and immunoblotted with anti-Flag, anti-




3.2.2 PP2A interaction with DLC1: EGF-dependent process 
 
 As shown by the Okadaic acid treatment, PP2A is a potential regulator 
of DLC1. Furthermore, this regulation seems to be downstream of EGF 
stimulation. Keeping this in mind all experiments were performed using EGF 
treatment. The cells were transfected with DLC1 and PP2AC-CS and 
stimulated with EGF. The cells were lysed at various time points post-EGF 
stimulation. It was observed that the maximal interaction between DLC1 and 
PP2A takes place at 10mins post-stimulation (Fig 3.5, top panel, lane 3), 
which also seems to be the peak in the phosphoERK cycle, hence reiterating 
that this regulation is indeed downstream of EGF stimulation and is probably 





Figure 3.5: The DLC1-PP2A-C-CS binding in HeLa JW cells is dependent 
on EGF stimulation. HeLa JW cells transfected with Flag-tagged DLC1 and 
myc-tagged PP2A-C-CS were starved for 18-24 hours in serum-free media 
and then stimulated with EGF (100ng/ml). The cells were lysed 0, 5, 10, 15 
and 30mins post stimulation and the whole cell lysates (WCL) were used for 
immunoprecipitation (IP) with M2 anti-Flag agarose beads. Proteins in the 
WCL and IP were separated by SDS-PAGE and immunoblotted with 
respective antibodies. The binding between DLC1 and PP2A-C-CS is 
dependent on EGF stimulation (top panel) with the binding profile mimicking 
that of the ERK1/2 phosphorylation profile (5
th
 panel from top) with a peak at 




3.2.3 Confirmation of site-specific binding between DLC1-PP2A 
 
 Different sets of mutants were created for the potential target site on 
DLC1 to elucidate their binding capabilities with PP2A. A deletion mutant 
encompassing the 5 serines in the region identified by phosphoproteomics was 
created, namely, DLC1-S (S304-S308). Fig 3.6 shows that DLC1-S does 
not interact with PP2A even upon EGF stimulation, thereby confirming that 
these might indeed be the target for PP2A-mediated dephosphorylation of 
DLC1. 
Residues T301 and S308 have previously been identified as loci that 
are prevalently mutated in DLC1 in cancer patients [Liao et al., 2008]. S308 
falls under the serine island identified by phosphoproteomics. To determine 
whether these residues might be targets of PP2A, they were mutated to 
Alanine and Aspartate creating the double mutants T301/S308A and 
T301/S308D. T301/S308A mutant acts as the phospho-dead mutant whereas 
the T301/S308D mutant acts as the phospho-mimetic mutant. 
Immunoprecipitation studies of these mutants with PP2Ac- CS revealed, as 
expected, that phospho-mimetic mutant of DLC1 binds much stronger than the 
phospho-dead mutant of DLC1, which even upon EGF stimulation did not 
show any interaction (Fig 3.7, top panel, lane 2-6). The phospho-mimetic 
mutant showed binding, but to a much lesser degree, even without stimulation, 
whereas the wild-type DLC1 binding occurred, as previously shown, only 
upon stimulation (Fig 3.7, top panel, lane 1-4). The preference of PP2AC 
towards the phospho-mimetic mutant of DLC1 indicates that T301/S308 is 
probably the site of dephosphorylation for PP2A. Also, to confirm that the 
binding is due to the activation of the Ras-MAPK pathway downstream of 
EGF stimulation, we carried out the binding between DLC1 mutants and 
PP2A in the presence of constitutively active Mek2 (Mek2-SD) and dominant 
negative Mek2 (Mek2-K). We observed the binding only in the presence of 
Mek2-SD and not Mek2-K for both wtDLC1 and DLC1-T301/308D. 
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Whereas, as with the previous experiment, DLC1-T301/S308A did not bind to 
PP2A (Fig 3.8). These results are similar to that observed with the binding 
done in the presence and absence of EGF stimulation. We can conclude that 
EGF stimulation activates the Ras-MAPK pathway which regulates the 
interaction. 
   Tf: myc-PP2AC 
 
Figure 3.6: DLC1-S binding with PP2A-C-CS upon EGF stimulation. 
HeLa JW cells were transfected with Flag-tagged DLC1 or Flag-tagged 
DLC1S and myc-tagged PP2A-C-CS. The cells were starved for 18-24 hours 
in serum-free media and then stimulated for 0 or 10mins with EGF (100ng/ml) 
as indicated. The cells were lysed and the whole cell lysates (WCL) were used 
for immunoprecipitation (IP) with M2 anti-Flag agarose beads. Proteins in the 
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WCL and IP were separated by SDS-PAGE and immunoblotted with the 
respective antibodies. The binding between DLC1 and PP2A-C-CS (top panel, 







Figure 3.7: PP2A-C-CS binding with DLC1 phospho-mimetic and 
phospho-defective mutants. HeLa JW cells were transfected with Flag-
tagged DLC1, Flag-tagged DLC1 (T301/S308D) and Flag-tagged DLC1 
(T301/S308A). The cells were starved for 18-24 hours in serum-free media 
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and then stimulated for 0 or 10mins with EGF (100ng/ml). The cells were then 
lysed and the whole cell lysate (WCL) were used for immunoprecipitation (IP) 
with M2 anti-Flag agarose beads. Proteins in the WCL and IP were separated 
by SDS-PAGE and immunoblotted with respective antibodies. PP2A-C-CS 
binds to the phosphor-mimetic DLC1 T301/S308D and not to the phosphor-
defective DLC1 T301/S308A suggesting that T301/S308 is a site of 





Figure 3.8: DLC1 interaction with PP2A is regulated by Ras-MAPK 
pathway downstream of EGF stimulation. HeLa JW cells were transfected 
with Flag-tagged DLC1, Flag-tagged DLC1 (T301/S308D) and Flag-tagged 
DLC1 (T301/S308A) as well as HA-Mek2-SD and HA-Mek2-K as indicated. 
Myc-PP2AC-CS was transfected into all wells. The cells were lysed and the 
whole cell lysates (WCL) were used for immunoprecipitation (IP) with M2 
anti-Flag agarose beads. Proteins in the WCL and IP were separated by SDS-
PAGE and immunoblotted with respective antibodies.  wtDLC1 and the 
phospho-mimetic DLC1 (T301/S308D) bind to PP2AC-CS in the presence of 
Mek2-SD (top panel, lanes 2 and 5 respectively) and not in the presence of 
Mek2-K (top panel, lanes 1 and 6). The phosphor-defective mutant DLC1 
(T301/S308A) does not bind to PP2AC-CS even with Mek2-SD indicating that 




3.3 Effect of PP2A regulation on DLC1 GAP activity 
 
   As seen previously, EGF stimulation is required for DLC1 GAP 
activity (Fig 3.1) as well as for PP2A interaction with DLC1 (Fig 3.5). We 
wanted to confirm whether these two events were correlated or independent of 
each other.  In addition, we wanted to check whether PP2A-mediated 
regulation of DLC1 by dephosphorylation had any direct effect on the 
RhoGAP function of DLC1 as it has been shown in previous studies that 
DLC1 can also be regulated to perform GAP-independent functions [Healy et 
al., 2008] 
3.3.1 Dephosphorylation mediated by PP2A regulates DLC1 GAP 
activity 
 
 To further explore the role of phospho-mimetic and phospho-defective 
mutants of DLC1 on its GAP activity, we performed the RhoGAP assay by 
transfecting HeLa JW cells with vector, wtDLC1, DLC1-R677E, DLC1-
T301/S308A and DLC1-T301/S308D. The sample set was subjected to EGF 
stimulation prior to lysis. Interestingly, the dephosphorylated-like form of 
DLC1, namely the phospho-dead mutant, and not the phosphorylated-like 
form (phospho-mimetic mutant) of DLC1 showed RhoGAP activity upon 
stimulation, which was similar to that of the wtDLC1 (Fig 3.9, top panel). This 
indicates that DLC1 has to undergo dephosphorylation by PP2A for it to be 
active. 
We created a deletion mutant for the serine-rich island identified via 
phosphoproteomics, namely, DLC1-S. With the DLC1-S mutant by-
passing the need for dephosphorylation, we hypothesized that DLC1 might get 
activated earlier. Hence, we proceeded to do a time-dependent EGF 
stimulation and compared the active RhoA levels between vector, wtDLC1 
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and DLC1-S in HeLa JW cells. Fig 3.10a shows that wtDLC1 has maximal 
activity at 10mins post-stimulation (Top panel, centre section), whereas 
DLC1-S seems to attain maximal activity earlier than wtDLC1 (Top panel, 
right section). It is also noteworthy to see that despite the deletion of the PP2A 
interacting sites, DLC1 still requires EGF stimulation for its activity. This 
attests the need for EGF stimulation and presence of another phosphorylation 




Figure 3.9: In vitro GAP activity of DLC1 phospho-defective and 
phospho-mimetic mutants. HeLa JW cells were transfected with Flag-tagged 
DLC1 and its mutants. The cells were starved for 18-24 hours in serum-free 
media and then stimulated for 0 or 10mins with EGF (100ng/ml). The cells 
were lysed and the whole cell lysate (WCL) were used for pull-down (PD) 
with glutathione sepharose 4B beads attached to GST-tagged RBD. Proteins in 
the WCL and PD were separated by SDS-PAGE and immunoblotted with 
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respective antibodies. EGF stimulation activates GAP activity of wtDLC1. 
The phospho-defective mutant DLC1 (T301/S308A) is also activated upon 
EGF stimulation whereas the phospho-mimetic mutant DLC1 (T301/S308D) 
remains inactive even with EGF stimulation. This indicates that DLC1 is 




                              
Figure 3.10: Time-dependent effect of EGF stimulation on the in vitro 
GAP activity of DLC1 and mutant. a) HeLa JW cells were transfected with 
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Flag-tagged DLC1, Flag-tagged DLC1-S and Flag-tagged vector. The cells 
were starved for 18-24 hours in serum-free media and then stimulated with 
EGF (100ng/ml) for time intervals of 0, 5, 10, 15 and 30mins. The cells were 
lysed and the whole cell lysates (WCL) were used for pull-down (PD) with 
glutathione sepharose 4B beads attached to GST-tagged RBD. Proteins in the 
WCL and PD were separated by SDS-PAGE and immunoblotted with 
respective antibodies.  b) shows the analysis done for RBD assay indicating 
the active levels of RhoA over time; n=3, p<0.05.  
 
3.4 DLC1-PP2A interaction: Is there another regulator?  
 
 To confirm the binding between DLC1 and PP2A, 
immunoprecipitation was carried out in 293T cell line. Surprisingly, unlike the 
interaction in HeLa JW cells the binding between DLC1 and PP2A did not 





Figure 3.11: DLC1-PP2A-C-CS binding in 293T cells. 293T cells were 
transfected with Flag-tagged DLC1 and myc-tagged PP2A-C-CS. The cells 
were starved for 18-24 hours in serum-free media and then stimulated with 
EGF (100ng/ml) for duration of 0, 5, 10, 15, 30mins. The cells were lysed and 
the whole cell lysates (WCL) were used for immunoprecipitation (IP) with M2 
anti-Flag agarose beads. Proteins in the WCL and IP were separated by SDS-
PAGE and immunoblotted with respective antibodies.  The interaction 
between DLC1 and PP2AC-CS occurs independent of EGF stimulation in 
293T cells. 
 
3.4.1 Focal Adhesion Kinase (FAK) check on DLC1-PP2A 
interaction 
 
 Since HeLa JW and 293T cells showed different binding pattern upon 
EGF stimulation, we wanted to check whether this effect was simply a cell-
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line dependent one or there was another molecule involved. We compared the 
lysates of HeLa JW and 293T and probed for various proteins which might 
potentially regulate this interaction. The proteins initially probed for were 
based on the prior knowledge of their interaction with DLC1. Interestingly, 
293T cells lacked total FAK and the active form of FAK pY397 but HeLa JW 





panel from the top). 
FAK has been previously shown to be a DLC1 interacting partner and 
is important for DLC1s tumor suppressive functions ([Li et al., 2011]. To 
confirm that the differential binding seen in HeLa JW and 293T was indeed 
because of FAK, we used two cell lines, namely, wild-type mouse embryonic 
fibroblasts (MEFs) and FAK-/- MEFs. The two cell lines were transfected 
with DLC1 and PP2AC and EGF stimulation was carried out before cell lysis. 
The immunoprecipitation study showed DLC1-PP2A interaction in wtMEFs is 
EGF stimulation dependent whereas it is not in the case of FAK-/- MEFs (Fig 
3.13). This proves that the interaction between the two proteins is not a cell 






                                                          
 
Figure 3.12: FAK expression profile in HeLa JW and 293T cells. HeLa JW 
and 293T cells were seeded in serum-containing media. The cells were lysed 
and the whole cell lysate (WCL) proteins were separated by SDS-PAGE and 
immunoblotted with respective antibodies. DLC1 is present in 293T cells and 
absent in HeLa JW cells whereas FAK is present in HeLa JW and absent in 





Figure 3.13: DLC1-PP2A-C-CS binding in wtMEFs and FAK-/- MEFs. 
wtMEFs (left) and FAK-/- MEFs (right) were transfected with Flag-tagged 
DLC1 and myc-tagged PP2A-C-CS. The cells were starved for 18-24 hours in 
serum-free media and then stimulated for 10mins with EGF (100ng/ml). The 
cells were lysed and the whole cell lysates (WCL) were used for 
immunoprecipitation (IP) with M2 anti-Flag agarose beads. Proteins in the 
WCL and IP were separated by SDS-PAGE and immunoblotted with 
respective antibodies. DLC1-PP2AC-CS interaction is dependent on EGF 
stimulation in wtMEF whereas in FAK-/- MEFs this interaction is independent 
of EGF stimulation. 
 
3.4.2 Inactivation of FAK by Ras-MAPK pathway allows for PP2A 
interaction with DLC1 
 
The next question we asked was- In what manner does EGF 
stimulation regulate FAK to mediate the binding between DLC1 and PP2A?  
The answer to this might lie in the inactivation of FAK by EGF. EGF 
stimulation- dependent phosphorylation of the S910 residue on FAK recruits 
Pin1 and PTP-PEST, a tyrosine phosphatase to FAK, leading to the 
dephosphorylation of Y397, which is important for FAKs active status [Zheng 
et al., 2009].   
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To determine the phosphorylation status of FAK upon EGF treatment, 
HeLa JW cells were subjected to EGF stimulation and were lysed at varying 
pre-fixed time points and the lysates were blotted for pS910, pY397 and 
panFAK. Fig 3.14a shows that at maximal activation of the Ras-MAPK 
pathway (10mins post stimulation), the pS910 levels was also maximum. In 
contrast the Y397 phosphorylation levels were the lowest at this time point, 
indicating that FAK was getting inactivated at this stage of stimulation. This is 
in concurrence with the EGF regulation of FAK phosphorylation that has been 
previously observed by others [Zheng et al., 2009] 







                            
Figure 3.14: EGF stimulation dependent change in FAK S910 and Y397 
phosphorylation. a) HeLa JW cells were seeded in 6-well plates. The cells 
were starved for 18-24 hours in serum-free media and then stimulated with 
EGF (100ng/ml) for 0, 5, 10, 15 and 30mins. The cells were lysed and the 
whole cell lysate (WCL) proteins were separated by SDS-PAGE and 
immunoblotted with respective antibodies. b) shows statistical analysis for the 
ratio of pY397 to total FAK present in the cells; n=3, p<0.05. 
 
To ensure that the FAK phosphorylation on S910 residue and the 
subsequent dephosphorylation on Y397 residue is downstream of the Ras-
MAPK pathway, we used U0126, a Mek/Erk inhibitor, followed by EGF 
stimulation and blotted for the different phosphorylated states of FAK. As 
shown in Fig 3.15, U0126 treatment reduces the S910 phosphorylation and 




Figure 3.15: U0126 treatment inhibits EGF-mediated change in 
phosphorylation of FAK S910 and Y397. HeLa JW cells were seeded in 6-
well plates. The cells were starved for 18-24 hours in serum-free media. This 
was followed by U0126 treatment for 1hr and EGF stimulation (100ng/ml) for 
0 and 10mins as indicated. The cells were lysed and the whole cell lysate 
(WCL) proteins were separated by SDS-PAGE and immunoblotted with 
respective antibodies. Upon EGF stimulation, the phosphorylation of FAK on 
S910 increases (2
nd
 panel, lane 2) and upon U0126 treatment, the levels of 
S910 phosphorylation decreases (2
nd
 panel, lane 3). A consequent increase in 
phosphorylation of Y394 on FAK is observed (top panel, lane 3) upon 
decrease of S910 phosphorylation.  
 
To confirm the regulation of DLC1-PP2AC-CS by FAK, we repeated 
the DLC1-PP2AC interaction in HeLa JW and 293T cells with FAK inhibitor 
treatment and over-expression of FAK respectively. We observed that the 
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binding profile of HeLa JW with FAK inhibitor treatment now matches that of 
293T without FAK over-expression and that of 293T with FAK over-
expression matches HeLa JW without the inhibitor treatment (Fig 3.16 and Fig 
3.17). We now conclude that FAK in its active form inhibits the DLC1-PP2A 
binding and upon FAK inhibition, this constraint is lifted, allowing the 
interaction to occur. 
 
 
Figure 3.16: DLC1-PP2A-C-CS binding in HeLa JW cells with and 
without FAK inhibitor treatment. HeLa JW cells were transfected with 
Flag-tagged DLC1 and myc-PP2A-C-CS. The cells were starved for 18-24 
hours in serum-free media, treated with FAK inhibitor (left) or DMSO (right) 
and then stimulated with EGF (100ng/ml) for 0, 5, 10, 15, 30mins. The cells 
were lysed and the whole cell lysates (WCL) were used for 
immunoprecipitation (IP) with M2 anti-Flag agarose beads. Proteins in the 
WCL and IP were separated by SDS-PAGE and immunoblotted with 
respective antibodies. Upon inhibition of FAK in HeLa JW cells, the DLC1-
PP2AC-CS interaction is independent of EGF stimulation (left) whereas under 





Figure 3.17: DLC1-PP2A-C-CS binding in 293T cells with and without 
FAK overexpression. 293T cells were transfected with Flag- DLC1, myc-
PP2A-C-CS and either mcherry-FAK (left) or mcherry-vector (right). The 
cells were starved for 18-24 hours in serum-free media and then stimulated 
with EGF (100ng/ml) for 0, 5, 10, 15, 30mins. The cells were lysed and the 
whole cell lysates (WCL) were used for immunoprecipitation (IP) with M2 
anti-Flag agarose beads. Proteins in the WCL and IP were separated by SDS-
PAGE and immunoblotted with respective antibodies. In 293T cells, upon 
transfection with FAK, the previously EGF independent binding of DLC1-
PP2AC-CS becomes dependent on EGF stimulation with a peak interaction at 





3.4.3 EGF stimulation controls DLC1 activity in a two-pronged 
manner 
 
FAK plays a major role in regulating the active RhoA levels. In FAK-
/- cells the intrinsic active RhoA levels are elevated. Also, FAK seems to be 
involved in inactivating RhoA [Orr et al., 2004]. We wanted to see how the 
interplay of DLC1, PP2A and FAK affected the GAP activity of DLC1. For 
this purpose we used inhibitors of FAK and PP2A, PF-573228 and Okadaic 
acid respectively and carried out the RhoGAP assay post-stimulation. In Fig 
3.18 we observed that DLC1 lacks GAP activity when treated with Okadaic 
acid (top right panel, lane 4) whereas upon FAK inhibitor treatment the GAP 
function of DLC1 is still retained (top right panel, lane 6). With or without 
treatment of either of the inhibitors, DLC1 gets activated only upon 
stimulation with EGF. This suggests that EGF stimulation is necessary but not 
sufficient to activate DLC1 RhoGAP function and it requires 
dephosphorylation by PP2A for full activity. This dephosphorylation event is 
control indirectly by EGF as well, because of its control on the active state of 
FAK, which in the absence of stimulation prevents PP2A from interacting 





Figure 3.18: In vitro GAP activity of DLC1 on endogenous RhoA upon 
Okadaic acid and FAK inhibitor treatment.  HeLa JW cells were 
transfected with Flag-tagged DLC1 (right) and Flag-vector (left). The cells 
were starved for 18-24 hours in serum-free media and then treated with 
Okadaic acid (OA), FAK inhibitor (FI) and/or EGF (100ng/ml) as indicated. 
The cells were lysed and the whole cell lysates (WCL) were used for pull-
down (PD) with glutathione sepharose 4B beads attached to GST-tagged 
RBD. Proteins in the WCL and PD were separated by SDS-PAGE and 
immunoblotted with respective antibodies. Treatment with OA overrides the 
activation of DLC1’s GAP activity brought about by EGF stimulation whereas 
treatment with FI has no effect on the activation of DLC1 upon EGF 
stimulation. 
 
3.5 DLC1 mediated change in cell spreading and motility 
 
DLC1 is a known tumor-suppressor and it is important to study the role 
of this protein in the process of cancer initiation and progression. It has been 
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seen that various cancers carry mutations in the DLC1 gene or it is entirely 
deleted from the genome [Durkin et al., 2007b]. For cancer progression, the 
affected tissues have to migrate from the region of origin to a different 
location and this is called metastasis. Cell migration is the first step in 
metastasis. Cell migration itself can be broken down to multiple steps, with the 
attachment and spreading of the cells on the extracellular matrix initiating the 
process. These processes are spatially and temporally controlled by 
RhoGTPases.  DLC1 expression in cells has been attributed to change in cell 
morphology as well as inhibition of directional cell migration [Kim et al., 
2008].  
 
3.5.1 DLC1 enhances cell spreading in a GAP-dependent manner 
 
We have elucidated a novel mechanism by which DLC1s activation is 
controlled in a temporal manner. Our next step was to extrapolate our findings 
to physiological functions and see the effect of DLC1-GAP activity on 
different yet connected cellular processes. We wanted to see if DLC1 has an 
effect on cell spreading as well and whether this was a GAP-dependent 
process. Cell spreading is a result of cyclic activation of Rac and RhoA. 
Decrease in cell spreading is a result of inhibition of membrane protrusion, 
mediated by Rho-dependent increase in cellular contractility. It has previously 
been shown that p190RhoGAP controls cell spreading in a RhoA-dependent 
manner [Arthur and Burridge, 2001]. We expected DLC1 to behave in a 
similar manner.  
HeLa JW cells transfected with vector-GFP, DLC1-GFP and DLC1-
R677E-GFP we plated as described in materials and methods and fixed at 
given time-points. The spreading trend for each sample was plotted over the 
course of 90minutes. We observed that in all cases, the spread area increased 
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over time Fig 3.19. To make the process of analysis simpler, we picked one 
constant time point across the sample sets for comparison (60 mins).  
Even without stimulation, DLC1-transfected cells spread much better 
than vector- and DLC1-R677E- transfected cells. With FAK inhibitor 
treatment, there is a drastic decrease in spread area in all the sample sets (Fig 
3.20). It has been previously shown that in FAK-/- cells, the levels of active 
RhoA are high. Increase in RhoA levels translates to higher contractility in the 
cells and as seen in the spreading experiment this decreases the spread area of 
the cells. Stimulating the cells with EGF reverses the effect of FAK inhibitor 
treatment alone, increasing the spread area of the cells transfected with DLC1 
(Fig 3.21). This corresponds to DLC1-mediated suppression of active RhoA 
levels in the cell. This effect is a GAP-dependent function because cells 
transfected DLC1-R677E, the GAP-dead mutant do not show change in spread 
area even upon EGF treatment and are comparable to the vector transfected 
































Figure 3.19: Spreading trend of cells over a period of 90mins: HeLa JW 
cells were transfected with GFP-vector, -DLC1 and –DLC1-R677E. Cells 
were subjected to different treatments as indicated. FI indicates FAK inhibitor 
treatment and EGF indicates EGF stimulation. The cells were plated and fixed 
at 0, 30, 45, 60 and 90mins. Spread area of the cells was calculated by drawing 
an outline of the cells using ImageJ software and measuring the area enclosed 





























































Figure 3.20: DLC1-transfected cells spread better, an effect that is 
reversed by FAK inhibitor treatment: HeLa JW cells were transfected with 
GFP-vector, -DLC1 and –DLC1-R677E. The cells were starved for 18-24 
hours in serum-free media and then subjected to different treatments as 
indicated. FI indicates FAK inhibitor treatment. Spread area of the cells was 
calculated by drawing an outline of the cells using ImageJ software and 
measuring the area enclosed in the outline. Annova was used for statistical 
analysis, n=160, p<0.05. The analysed data shown is for cells fixed 60mins 
post-plating. The different alphabets are indicative of statistical significance 





Figure 3.21: EGF stimulation reverses the effect of FAK inhibitor 
treatment: HeLa JW cells were transfected with GFP-vector, -DLC1 and –
DLC1-R677E. The cells were starved for 18-24 hours in serum-free media and 
then subjected to different treatments as indicated. FI indicates FAK inhibitor 
treatment and EGF indicates EGF stimulation. Spread area of the cells was 
calculated by drawing an outline of the cells using ImageJ software and 
measuring the area enclosed in the outline. Annova was used for statistical 
analysis, n=160, p<0.05. The analysed data shown is for cells fixed 60mins 
post-plating. The different alphabets are indicative of statistical significance 





Figure 3.22: Cell spreading is a GAP-dependent function of DLC1: HeLa 
JW cells were transfected with GFP-vector, -DLC1 and –DLC1-R677E. The 
cells were starved for 18-24 hours in serum-free media and then subjected to 
different treatments as indicated. FI indicates FAK inhibitor treatment and 
EGF indicates EGF stimulation. Spread area of the cells was calculated by 
drawing an outline of the cells using ImageJ software and measuring the area 
enclosed in the outline. Annova was used for statistical analysis, n=160, 
p<0.05. The analysed data shown is for cells fixed 60mins post-plating. The 
different alphabets are indicative of statistical significance with respect to each 
other and the error bars denote standard error. 
 
To confirm the GAP-dependence of the spreading capabilities of the 
cells, they were transfected with the phospho-mutants of DLC1, namely, 
DLC1-T301/S308A and DLC1-T301/S308D. These two mutants showed 
106 
 
differential RhoGAP activity, with phospho-dead mutant GAP activity 
mimetic the wtDLC1 and the phospho-mimetic mutant activity being similar 
to DLC1-R677E. The cell spreading experiment indeed confirms that the 
alanine mutant spreads better than the aspartate mutant (Fig 3.23 and Fig 
3.24). This shows that the novel mechanism of regulation of DLC1 comes into 
play as early as spreading.  
 
 
Figure 3.23: Phospho-defective mutant cell spreading pattern is similar to 
that of wtDLC1: HeLa JW cells were transfected with GFP-DLC1, DLC1-
T301/S308A and –DLC1-T301/308D. Cells were subjected to different 
treatments as indicated. The cells were starved for 18-24 hours in serum-free 
media and then subjected to different treatments as indicated. FI indicates 
FAK inhibitor treatment and EGF indicates EGF stimulation. Spread area of 
the cells was calculated by drawing an outline of the cells using ImageJ 
software and measuring the area enclosed in the outline. Annova was used for 
statistical analysis, n=160, p<0.05. The analysed data shown is for cells fixed 
60mins post-plating. The different alphabets are indicative of statistical 
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significance with respect to each other and the error bars denote standard 
error. 
   
 
Figure 3.24: Phospho-mimetic mutant cell spreading pattern is similar to 
that of DLC1-R677E: HeLa JW cells were transfected with GFP-DLC1-
R677E, DLC1-T301/S308A and –DLC1-T301/308D. The cells were starved 
for 18-24 hours in serum-free media and then subjected to different treatments 
as indicated. FI indicates FAK inhibitor treatment and EGF indicates EGF 
stimulation. Spread area of the cells was calculated by drawing an outline of 
the cells using ImageJ software and measuring the area enclosed in the outline. 
Annova was used for statistical analysis, n=160, p<0.05. The analysed data 
shown is for cells fixed 60mins post-plating. The different alphabets are 
indicative of statistical significance with respect to each other and the error 





3.5.2  DLC1 inhibits cell migration only upon EGF stimulation 
 
Deregulation of the RhoGTPases, decreases cell polarity leading to the 
loss of directional cell migration. It has been previously shown that DLC1 
impairs wound healing. This is mainly due to the reduction in the 
directionality and not due to the decreased velocity. In the light of the steps 
that might be leading to activation of DLC1, we wanted to see how the 
aforementioned treatments affect the migration of the cell. When cells were 
transfected with DLC1, vector and DLC1-R677E, DLC1 seemed to impair the 
closure of the wound only upon EGF or EGF/FAK inhibitor treatment (Fig 
3.25a and b).  
 
 
Figure 3.25 a: DLC1 requires EGF stimulation to be able to inhibit cell 
migration: HeLa JW cells were transfected with GFP-vector, -DLC1 and –
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DLC1-R677E. The cells were starved for 18-24 hours in serum-free media and 
then subjected to different treatments as indicated. FI indicates FAK inhibitor 
treatment and EGF indicates EGF stimulation. The area covered by the cells 
during migration was calculated using ImageJ software. The first and the last 
time point of the migration were used to outline the edges of the cell 
monolayer. The area between the edges were calculated and area of last time 
point was deducted from the starting time point to give the area migrated by 
the cells. Annova was used for statistical analysis, n=4, p<0.05. The * 
represents treatments that are statistically significant with respect to other 
treatments and the error bars denote standard error. 
EGF                       -                                      +                                 -                               + 
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Figure 3.25b: Cell migration: This is representative data of the images 
obtained for the cell migration experiment done. For Vec, DLC1 and 
R677E the top panel is the image of the wound at 0hrs and the bottom 






























4   DISCUSSION 
 
4.1 EGF-mediated MEK-ERK activation acts as a master key to 
unlock DLC1 GAP activity  
 
 Information on DLC1s GAP function has always asserted that GAP 
domain of DLC1 alone is not an active domain and requires regions around it 
to function as a GAP [Kim et al., 2008]. Previously done work has shown that 
various posttranslational modifications regulate RhoGAP activity of DLC1 
either directly or by mediating protein-protein interactions. Akt 
phosphorylation of DLC1 at S567 inhibits the GAP activity [Ko et al., 2010b], 
whereas S440 and Y442 phosphorylation mediates DLC1 interaction with the 
tensins which in turn is important for its RhoGAP function [Chan et al., 2009; 
Yam et al., 2006]. Recent work also shows that phosphorylation of DLC1 by 
PKA at S549 is important for its dimerization and this regulates DLC1 
function as well [Ko et al., 2013].  
 
4.1.1 Activation of DLC1-GAP function: A two-step process 
 
 We recently found that EGF-mediated activation of the Ras-MAPK 
pathway is involved in the activation of DLC1. This activation is carried out in 
a two-step process, which involves two other proteins, namely, FAK and 
PP2A. The first step in this process is the phosphorylation of DLC1. We found 
that DLC1 get phosphorylated (Fig 3.2) upon EGF treatment and this mediated 
through the Ras-MAPK pathway as demonstrated by the U0126 treatment. But 
this phosphorylation event does not activate DLC1. This was shown by 
Okadaic acid, a PP2A inhibitor, treatment. It was seen that upon stimulation, 
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in the event that PP2A is inhibited, DLC1 is still inactive (Fig 3.18). This 
shows that DLC1 also has to undergo PP2A mediated dephosphorylation to be 
activated. The sites identified by phosphoproteomics show that, EGF primes 
DLC1 for interaction and eventual dephosphorylation by PP2A (Table 3.1). 
But interaction between DLC1 and PP2A is not a simple event of priming 
mediated by the Ras-MAPK pathway. It also requires the inactivation of FAK, 
which interferes with DLC1-PP2A interaction. This is the second step in the 
EGF-mediated activation of DLC1. FAK inactivation is carried out by the 
ERK-mediated phosphorylation of FAK at S910, making it a target for PTP-
PEST, which dephosphorylates Y397 thus inactivating FAK [Zheng et al., 
2009]. This inactivation allows for DLC1-PP2A interaction leading to the 
dephosphorylation of DLC1 and hence its activation. 
  
4.1.2 Phosphorylation of DLC1 at site(s) other than those targeted by 
PP2A is essential for active GAP function 
 
 To ensure that the target sites found for PP2A were indeed the ones 
necessary for DLC1 function by dephosphorylation; we substituted Ser for Ala 
to create a phospho-dead mutant. Unexpectedly this mutant is inactive unless 
the cells were stimulated with EGF (Fig 3.9). To rule out the functionality of 
these sites in the activation process, we created phospho-mimicking mutant 
which contains Ser to Asp substitution. Surprisingly, this mutant was inactive 
even upon EGF stimulation (Fig 3.9), indicating that the dephosphorylation of 
the residues was an important step in the activation of DLC1-GAP function. 
This led us to the conclusion, that the event of EGF stimulation triggering the 
downstream Ras-MAPK pathway itself is important. This could possibly be 
due to presence of sites other than those targeted by PP2A which are 
phosphorylated by EGF that are necessary for the RhoGAP activity, answering 
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our question of how important EGF really is to this regulation. The 
phosphorylation of these other sites might be directly responsible or might be 
priming DLC1 for interaction with other proteins which are responsible for the 
GAP activity.  
 
4.1.3 EGF stimulation allows for temporal activation of DLC1 
 
 Why is it necessary for DLC1 to contain multiple sites downstream of 
EGF? What regulatory advantage do multiple phosphorylation sites, which 
need to be dephosphorylated for DLC1s GAP activity, give DLC1? For 
directional cell migration, it is important that RhoGTPases are regulated in a 
spatial and temporal manner. With GAPs and GEFs controlling the activation 
status of RhoGTPases, it is necessary that these proteins are also under a tight 
regulation to ensure a cyclical activity of Rho, Rac and Cdc42. Activation of 
DLC1 by EGF is possibly one such temporal control. ERK activation by EGF 
is a cyclical process. Phosphorylation of ERK is seen within a couple of 
minutes of EGF stimulation. The levels reach a maximum and then drop 
before recovering again. With DLC1 phosphorylation and the 
dephosphorylation mediated by PP2A being dependent on pERK, it is possible 
that DLC1 gets phosphorylated at an earlier stage of ERK activation, which is 
followed by interaction with PP2A and dephosphorylation at a later stage 
when pERK levels reach a maximum.  Hence, this cyclical ERK activation 
could in turn be controlling DLC1 activation in a time-dependent manner.   
 With the knowledge we have about the steps leading to the activation 











4.2 DLC1-PP2A interaction: What is the role of activated FAK? 
 
We have shown that DLC1-PP2A interaction occurs only upon 
inactivation of FAK (Fig 3.16 and Fig 3.17). The question arises as to how the 
inactivation of FAK mediates this interaction? The two possibilities are that 
FAK interaction with DLC1 prevents the interaction of PP2A with DLC1 or 
FAK being a tyrosine kinase mediates inactivation of PP2A.  
 FAK, being a tyrosine kinase could be directly affecting PP2A by 
phosphorylation. It has been shown that phosphorylation of Y307 in the 
catalytic subunit of PP2A (PP2AC) transiently inactivates PP2A. This 
phosphorylation is carried out by Src [Chen et al., 1992], which in turn 
requires FAK for α5β1 integrin mediated activation, although Src in some 
cases can be activated independent of FAK [Wu et al., 2008]. We have shown 
that in Hela JW cells that upon FAK inhibitor treatment the binding profile of 
DLC1-PP2AC is altered (Fig 3.17). It is possible that inhibition of FAK 
prevents the activation of Src, thereby preventing further phosphorylation of 
Y307, allowing PP2A to be active. PP2A could also be activated directly 
downstream of Ras/MAPK pathway. As seen in Fig 3.5, PP2A interaction 
occurs only at the stage where the EGF pathway is maximally activated at 
which point FAK gets inactivated.  So is it necessary for PP2A to be activated 
to be able to bind to its substrates? If not, then what prevents DLC1-PP2A 
interaction?  
 FAK is known to interact with DLC1 with its FAT domain to the LD-
like motif on DLC1. This LD-like motif lies between the residues 469-476 
amino acids [Li et al., 2011]. The site of interaction for PP2A lies just 
upstream of these residues (Table 3.1).  Both FAK and PP2A are large 
proteins, as well as, the serine-rich region is highly unstructured and with the 
binding of FAK, it might sterically hinder the binding of PP2A to DLC1. 
Information on as to whether DLC1-FAK interaction is dependent on the 
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active state of FAK is unavailable. The first question that needs to be 
answered is if Y397 phosphorylation of FAK is important for its interaction 
with DLC1. If the answer to this question is yes, it might shed some light on 
the possibility of steric inference. It would also explain the inactivation of 
FAK by Ras-MAPK, leading to the binding of PP2A, as this would remove 
any physical constraints for the interaction to take place.  
 
4.3 Ras/MAPK-mediated DLC1 activation: A possible feedback loop  
 
The Ras/MAPK pathway is one of the signalling cascades that are 
activated downstream of the EGF-receptor and is one of the best characterized 
pathways. Physiological functions regulated by this pathway include cell 
growth, division and differentiation; cell cycle regulation, integrin-mediated 
signalling and cell migration. Dysregulation of this signalling cascade is 
therefore very frequently observed in tumorigenesis [Mor and Philips, 2006]. 
This pathway begins with the binding of epidermal growth factor (EGF) to the 
EGFR activating the tyrosine kinase activity of the cytoplasmic domain of the 
receptor leading to auto-phosphorylation. This allows for docking proteins 
containing SH2 domain like GRB2 to bind to the phosphotyrosine residues of 
the receptor. Via its two SH3 domains GRB2 binds to SOS, a GEF, activating 
it. This in turn activates the Ras/MAPK cascade [Zarich et al., 2006]. GRB2-
mediated activation can also be downstream of PDGFR and FGFR.   
Activation of FAK leads to its binding with Src, forming a complex 
which is essential for Src activation and for complete activation of FAK. In 
this activated complex, Src phosphorylates the Tyr925 residue on FAK, 
creating a GRB2 binding site. This binding is a mechanism by which integrin 
engagement leads to activation of the Ras/MAPK pathway via FAK through 
its binding to GRB2 [Schlaepfer et al., 2004]. The phosphorylation of ERK 
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leads to the activation of the myosin light chain kinase. This is important for 
the modulation of the focal adhesion dynamics in migrating cells [Mitra et al., 
2005]. 
 We have shown that MEK/ERK mediated phosphorylation of DLC1 
(Fig 3.2) is important for DLC1s RhoGAP function (Fig 3.1). Previous studies 
have shown that upon over-expression of DLC1, FAK undergoes 
dephosphorylation at two residues, namely, Tyr397 and Tyr925 [Kim et al., 
2008]. With the dephosphorylation of Tyr925 the downstream ERK activation 
is inhibited preventing further or continuous activation of DLC1, completing 
the feedback loop.  
4.4 Mechanical cues to biochemical signalling  
  
All organisms ranging from bacteria to higher eukaryotes respond to 
mechanical stimuli, which are important for various physiological as well as 
pathophysiological processes. This event of conversion of physical stimuli to a 
biochemical response is known as mechanotransduction. Change in 
physiological characteristics due to physical forces is seen in the morphology 
of the heart, shape of the bone structure to the sensory responses like touch 
and hearing. Coordinated tissue growth and cell migration are a result of this 
event as well. And at a more molecular level, these physical forces also lead to 
conformational changes in proteins, which can act as a trigger in signalling 
events. The mechanical stimuli can be in the form of stress, pressure, tension 
etc and are translated into biochemical signals through specialized molecules 
called mechanotransducers. These are capable of sensing the change in the 
physical environment and undergo a conformational change to start the 
biochemical signalling. Cancer can be also a result of failure of a system to 
respond to these mechanical signals [Orr et al., 2006]. 
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In processes like embryonic development, the stiffness of the 
surrounding tissue environment and the contractile forces exerted by the cells 
in response to the environment are the two major physical stresses seen. These 
two factors are important for mechanotransduction. The interplay between 
these two mechanical stressed is important for the process of embryogenesis 
[Wozniak and Chen, 2009].  
4.4.1 Role of integrins in mechanotransduction 
Focussing at a more cellular level, the external environment consists of 
a diverse collection of connective tissue components which together form the 
extracellular matrix (ECM). The cells react to both forces that are generated 
via the interaction with ECM (externally) or internally [Bershadsky et al., 
2003; Chen, 2008]. These responses are bring about changes either locally, 
which affects the adhesion sites or globally that lead to a signalling cascade 
bringing about changes in the different physiological processes [Geiger et al., 
2009]. For the purpose of detecting the signals in a coherent manner there has 
to be sensing machinery in the cell. Integrins, a family of transmembrane 
receptors found at adhesion sites are one such example which helps in 
recognition of different substrate properties ranging from biochemical to 
physical attributes. Integrin engagement induces the formation of focal 
adhesions. Focal adhesions are points where the cell physically adheres to the 
ECM as well as within the cell is the link with the cytoskeletal network, thus 
acting as a scaffold for further downstream cascades. At the adhesion sites, 
integrins associate with a diverse range of proteins which are part of 
biochemical signalling pathways [Geiger and Bershadsky, 2002; Geiger et al., 
2001; Riveline et al., 2001]. 
 Upon a physical cue, integrins respond by a structural change, 
allowing the adhesion-associated proteins to bind to it and triggering the 
signalling cascade that activate G-protein or phosphorylation-mediated 
pathways. mDia1 and ROCK activation downstream stream of Rho activation 
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leads to actin polymerization and increase in contractility of the cell, 
respectively, which promote the assembly of focal adhesions. This can also be 
carried out by activation of Src kinases [Riveline et al., 2001; von Wichert et 
al., 2003]. This change in cytoskeletal dynamics brings about changes in cell 
shape and motility and eventually affecting cell processes such as 
proliferation, differentiation and cell survival. The activated adhesions 
themselves generate forces via the actomyosin network. This process is a 
feedback loop, with integrins being responsible for both sensing and response 
modules [Geiger et al., 2009].  
4.4.2 FAK-mediated regulation of RhoGTPases  
Small GTPases play a crucial role in the process of relaying 
biochemical information from the mechanical stresses that translate into 
changes in the cell, making their regulation even more important. Hence the 
factors regulating the regulators, namely, GEFs and GAPs in response to 
integrins-mediated signalling become key players in the process of 
mechanotransduction [Geiger et al., 2009]. One such example is FAK. FAK 
associates with integrins clusters through its ability to bind with focal adhesion 
associated proteins such as paxillin, talin and p130Cas. This interaction leads 
to activation of FAK and Src Kinases leading to downstream signalling [Mitra 
et al., 2005]. It has been shown that there is FAK-mediated change in cell 
behaviour upon mechanical stimulus. This could be due to a conformational 
change causing the Y397 site to be exposed [Wang et al., 2001]. 
Phosphorylation of this site leads to FAK activation which is necessary for its 
various functions. FAK has been seen to act on p190RhoGEF and 
p190RhoGAP, by phosphorylating and activating both the molecules in a 
temporal as well as spatial manner [Tomar and Schlaepfer, 2009].  Thus FAK 
is responsible for transducing the physical forces as read by the integrins into 




4.4.3 Does DLC1 regulation have a role to play in mechanotransduction? 
Recent study showed that FAK binds to DLC1 and has been shown to 
be important for its tumor suppressive functions [Li et al., 2011]. We have 
shown that FAK is also involved in regulating the RhoGAP function of DLC1 
by inhibiting PP2A interaction with DLC1. ERK phosphorylation, that is 
essential to the activation of the RhoGAP activity of DLC1, can be stimulated 
downstream of FAK. ERK itself is seen to respond to mechanical cues leading 
to activation of its effectors without the involvement of FAK. With ERK 
responding to mechanical cues, either directly or indirectly through FAK 
[Martineau and Gardiner, 2001; Weyts et al., 2002], it is possible that DLC1 
will play an important role in regulating the conversion of physical forces to 
biochemical process, eventually leading to the control of cellular dynamics. 
  
4.5 Conclusions and future perspectives 
  
 In this study we have identified a novel EGF stimulation-mediated 
regulation of DLC1 RhoGAP function through FAK and PP2A. We have 
shown PP2A to be a novel binding partner for DLC1. The potential target sites 
for PP2A identified on DLC1 downstream of EGF stimulation and OA 
treatment were T301 and S308, which have been previously identified as 
residues that were seen to be highly mutated in cancer samples as compared to 
normal human tissue samples. These residues have been shown to be 
indispensable to the DLC1-PP2A interaction. Our study also shows that FAK, 
a previously identified binding partner of DLC1, needs to be inactivated in 
order for this binding to occur.  
 This lead us to delineate a temporally control DLC1 activation in 
which activated MEK/ERK acts as a “master key” by not only 
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phosphorylating DLC1 and hence priming it for activation but also 
inactivating FAK thereby allowing DLC1 to interact with PP2A. This 
interaction leads to dephosphorylation of DLC1, leading to its complete 
activation. The phosphorylation of DLC1 occurs in the initial stages of 
MEK/ERK activation which is followed by FAK inactivation once the 
phosphoERK levels reach a maximum.  
 With multiple key players in this regulation, there were many 
questions raised during the process of the study. 
 
Is PP2A activation dependent on phosphorylation upon EGF stimulation 
or dephosphorylation upon FAK inhibition? 
 
PP2A-mediated interaction followed by dephosphorylation occurs only 
upon maximal activation of the EGF pathway as seen by the pERK levels. 
This observation leads us to the question if PP2A activity and its ability to 
interact with its substrates correlated. It has been shown that crude lysates can 
be used to detect the catalytic activity of the enzyme using colorimetric assay 
[McAvoy and Nairn, 2010]. Lysates of cells transfected with PP2AC lysed at 
various time points downstream of EGF stimulation can be used to check for 
the active catalytic function of PP2A. Comparison of colorimetric data with 
the existent immunoprecipitation data will divulge the correlation between the 
PP2A’s ability to interact and its active status. 
Also, it is important to study how exactly EGF stimulation brings 
about activation of PP2A. As discussed, PP2A can be inactivated by Src-
mediated Y307 phosphorylation. It will be paramount to see if this inactivation 
by Src is an FAK controlled event. For this purpose, FAK inhibitor treatment 
followed by SDS-PAGE and immunoblotting can be used to check for the 
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pSrc levels and pY307-PP2A levels. A change in pY307 levels upon FAK 
inhibitor treatment will show the effect of FAK on PP2A 
activation/inactivation. Also, quantifying pSrc levels will also tell us if FAK 
being a tyrosine kinase, can directly phosphorylate PP2A or whether its effects 
are mediated downstream of Src inactivation.  
 
Does FAK play a physical role in preventing the DLC1-PP2A interaction? 
  
A previous study has shown FAK-DLC1 interaction and the 
importance of the LD-like motif present on DLC1 which is necessary for the 
interaction [Li et al., 2011]. Also, we have, in our study shown DLC1-PP2A 
interaction and delineated the residues which are required for this interaction. 
As discussed in our first question, FAK could be leading to the inhibition or 
EGF stimulation could be responsible for the PP2A activation. Though the 
interacting sites are known, the requirements for the various interactions are 
unknown. Using immunoprecipitation, SDS-PAGE and western blotting, we 
can characterize binding between DLC1-FAK in a time-dependent manner 
post EGF stimulation. Blotting for pY397 and total FAK in the 
immunoprecipitates will answer the question as to whether the binding 
between DLC1-FAK is dependent on the activated state of FAK or not. Also, 
we have shown the binding between DLC1-PP2A is a stimulation-dependent 
characteristic (Fig 3.5). Comparing this profile to the DLC1-FAK binding will 
give us clues to whether FAK and PP2A can bind DLC1 simultaneously or if 
PP2A interaction requires FAK to detach itself from DLC1. This will also 
explain if there is competition and/or any form steric hindrance from FAK to 




Cell migration: Is it a GAP-dependent or independent function? 
 
It has been previously shown that DLC1s role in cell migration is a 
GAP-independent process as the GAP-inactive mutant of DLC1, R677E also 
prevents the wound from healing. Its ability in wound closure is more similar 
to DLC1 than vector as expected [Kim et al., 2008]. The cell migration 
experiment performed in this study seems to contradict it.  
 
 
Comparing the various treatments, we can see that DLC1s ability to 
inhibit wound closure is seen only upon EGF stimulation or EGF stimulation 
and FAK inhibitor treatment. These two treatment conditions were previously 
seen to be associated with DLC1 RhoGAP activity. Comparing the DLC1 and 
vector data with various treatments, this process seems to be a GAP-dependent 
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function. This is in contradiction with the previously published data which all 
show that transfection of DLC1 is alone sufficient to inhibit migration [Kim et 
al., 2007]. This can be explained by the fact that during the course of the 
wound healing experiment performed in our lab, cells were subjected to 
serum-free media, whereas the previously conducted experiments were carried 
out in serum-containing media. Hence there is some amount of activated 
MEK/ERK in media which might be sufficient for DLC1 activation and hence 
the observed results.  
DLC1-R677E does not seem to have any effect on the process of 
wound closure as seen in the first three cases which are similar to effect seen 
in vector-transfected cells. But upon EGF stimulation and FAK inhibitor 
treatment, the ability of the R677E cells seems to increase. Even though this 
does not indicate towards a GAP-independent effect on cell migration, it does 
raise many questions regarding the probable causes for the seen effect. DLC1 
is a protein with multiple domains, which have been shown to play a role in 
various GAP-independent tumor suppressive functions. It is possible that the 
effect on cell migration could be a concerted action of the various domains 
and not completely GAP-independent. Also, the role of FAK inhibitor needs 
to be characterized. It has to be kept in mind that the wound healing 
experiment is carried out over a period of 50hrs with no supplementation of 
the various treatments, which could also indicate wearing off of the effect of 
the various treatments. 
 To account for the various inconsistencies, the wound healing 
experiment can be carried out with the DLC1 mutants created during the 
course of this project, namely DLC1-T301/S308A and DLC1-T301/S308D. 
Also, the RhoGAP activity assay can be carried out after a 50hr treatment to 
mimic the conditions used during this experiment. The interpretation of the 
combined results could give us a better insight into the GAP-dependency of 
the process as the two mutants have been shown to have difference in 
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RhoGAP activity. Use of various available truncation mutants of DLC1 would 
also delineate the role of the other domains in this process.  
   
What is the mechanism by which EGF stimulation-mediated 
phosphorylation of DLC1 control its RhoGAP function? 
  There are a multitude of growth factors that are responsible for 
regulating cell process and dysregulation of the signalling cascades 
downstream of the growth factor receptors leads to cancer. EGF-mediated 
regulation of DLC1 is one of the first studies on effect of growth factors on 
DLC1s function. We have shown that EGF apart from priming DLC1 for 
PP2A-mediated dephosphorylation also phosphorylates other residues which 
are essential for DLC1s GAP activity. In this study we were unable to 
delineate the residues which upon EGF phosphorylation regulate the RhoGAP 
activity. A more high-throughput study would be required to do so. 
Phosphoproteomics combined with mutation studies can be used for this 
purpose.  
 DLC1 has been shown to be subject to various phosphorylation-
mediated regulation which affects its GAP activity. This is as a result of the 
effect of direct phosphorylation or phosphorylation-mediated interactions with 
other proteins which then regulate the localization and hence its activity.  Akt 
phosphorylation on  S567 leads inhibition of DLC1 GAP function [Ko et al., 
2010a].  On the other hand phosphorylation of residues S327 and S341 allows 
14-3-3 interaction with DLC1 and inhibits its activity as is the case with Y442 
phosphorylation which is necessary for interactions with Tensin and hence 
controls DLC1s localization [Qian et al., 2007; Scholz et al., 2008].  
 Identification of the residues on DLC1 will give us insights into 
possible interacting partners which might be responsible for regulating the 
localization of DLC1 and hence its activity. Also, it will be interesting to see 
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the RhoA binding ability of the phospho-mimic and phospho-defective mutant 
DLC1. It is possible that phosphorylation of DLC1 either opens up the 
structure or stabilizes the highly unstructured region of DLC1, allowing it to 
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